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Anaemia is one of the most common health problems worldwide and is prevalent in every 
population at every age. It is characterised by a lowered concentration of haemoglobin 
(Hb), the oxygen-transporting protein carried by erythrocytes. The most common 
symptoms include fatigue, weakness, difficulty concentrating and general malaise. 
Globally the most common aetiology is iron deficiency anaemia (IDA). Other leading 
causes, such as anaemia of chronic disease (ACD) and chronic kidney disease, vary 
considerably by geography, age, and gender1.   
The World Health Organisation (WHO) has defined anaemia by determining haemoglobin 
cut-off values, shown in Table 1. The overall prevalence of WHO-defined anaemia in the 
complete world population was estimated to be 32.9% in 2010, with the highest burden 
found in children below the age of five years1. In a community-dwelling population, the 
prevalence was determined to be lowest in men in the age group 17-49 years. From the 
age of 50 years the prevalence starts rising for both men and women, peaking above 20% 
in the age group 85+ years2 (Figure 1). Estimations of the incidence of anaemia vary widely 
and range from 12.8 to 90.2/1000 person-years in men and from 10.9 to 69.1/1000 
person-years in women3,4. 
 Haemoglobin < g/dL 
Age 5+ years  
Men 13.0 
Women, non-pregnant 12.0 
Women, pregnant 11.0 
Age < 5 years  
Men 12.0 
Women 12.0 
Table 1, WHO-defined haemoglobin cut-off levels for the diagnosis of anaemia1.  
Anaemia in general practice 
The increasing prevalence of anaemia with age has long been explained as an innocent 
consequence of aging.  During the last decade, however, many studies have been 
published detailing the detrimental effect on health aspects and mortality associated with 
anaemia (discussed below). The current remedy for anaemia is successful treatment of the 
underlying condition. Treatment of anaemia itself, i.e. the decreased haemoglobin level, is 
still limited5,6. Increased awareness among physicians about the prevalence of anaemia, its 
causes and its potential effects may improve this. Since anaemia is a common finding in 
general practice, it is crucial for general practitioners (GPs) to have a good understanding 
of the prevalence of the possible causes they may encounter. It is also important that the 
guidelines developed to aid GPs with the evaluation of anaemia are accurate. Many 
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consensus-based algorithms currently in use still focus on the traditional classification of 
anaemia aetiology based on the mean corpuscular volume (MCV) of the erythrocyte7-10. 
 
Figure 1, Percentage of persons considered anaemic according to the WHO standard, 
stratified by age and gender. Data taken from NHANES III (1998 to 2004) comprising a 
community-dwelling population in the United States. Adapted from Guralnik et al, 20042. 
This classification was developed by Wintrobe in the 1930s and has remained the 
prevailing division ever since11. While its exact validity in general practice is unclear, data 
from hospitalised patients indicates that MCV does not accurately reflect the underlying 
aetiology in the elderly and is practically useless when deciding on ordering further or 
more specific diagnostic tests12-14.  
Aetiology 
Anaemia itself is considered a symptom and secondary to the underlying aetiology, which 
needs to be properly diagnosed to allow for appropriate treatment and correction of the 
haemoglobin level. It is often multifactorial and the underlying aetiology is very diverse. As 
a result, determining the correct diagnosis is often challenging. Most analyses of anaemic 
populations focus on four main categories of aetiology: anaemia of chronic disease (ACD, 
sometimes referred to as anaemia of inflammation (ACI)), renal anaemia, nutrient 
deficiency (iron, vitamin B12 and/or folic acid) and unknown anaemia. An overview of the 
prevalence rates of these causes in community-dwelling populations is shown in Figure 22-
4,15-23.  
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Anaemia of chronic disease (ACD) 
ACD is the most common cause in an elderly population (≥ 50 years),  generally developing 
alongside conditions such as acute or chronic infections, organ failure, trauma, 
malignancy, and autoimmune or inflammatory disorders24-33. It is characterised by the 
retention of iron within macrophages and a reduced iron uptake from food. These effects 
are due to raised levels of hepcidin, a key regulator of iron metabolism34, and limit the 
availability of soluble iron for erythrocyte production despite adequate iron stores, leading 
to a functional iron deficiency (Figure 3)25. 
 
Figure 3, A schematic overview of the role of hepcidin in functional iron deficiency 
observed in anaemia in chronic disease 
Renal anaemia 
Renal anaemia is common among the elderly, due to a decline in renal function with age35, 
and is usually related to a decreased erythropoietin (EPO) production36-38. Even at modest 
degrees of renal insufficiency, a decrease in haemoglobin can already be observed36,39. 
Figure 2 (next page), an overview of the prevalence of ACD/ACI, renal anaemia, nutrient 
deficiency, unknown anaemia and other (if applicable) in several community-dwelling 
populations2-4,15-23.  
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EPO replacement therapy may resolve anaemia secondary to renal insufficiency and is 
used in, for example, patients with end-stage renal disease40,41. Often patients with renal 
anaemia also display features of ACD, due to low grade inflammation associated with 
renal insufficiency42.  
Nutrient deficiency 
The most common nutrient deficiency worldwide is iron deficiency1,43. In the Western 
world, the prevalence of iron deficiency anaemia (IDA) is about 15 to 20% in community-
dwelling populations (≥ 50 years)
4,17,19-22. In this population IDA usually results from 
gastrointestinal blood loss, which is associated with esophagitis, gastritis, diverticulosis, 
angiodysplastic lesions, gastric or duodenal ulcers, colorectal or gastric malignancies or 
premalignant polyps44-46. In industrialised countries iron deficiency is rarely caused by 
insufficient dietary intake, but this is regularly encountered in the developing world1,47.  
The primary cause of vitamin B12 and/or folic acid deficiency is an inadequate dietary 
intake of these nutrients. Malabsorption due to gastric atrophy or pernicious anaemia may 
lead to vitamin B12 deficiency48,49. The loss of intrinsic factor, vital for the absorption of 
vitamin B12, will lead to the loss of ability to absorb the vitamin50. An uncorrected vitamin 
B12 deficiency may result in bone marrow failure and demyelinating nervous system 
disease50. Both intestinal malabsorption and excessive alcohol intake may cause a folic 
acid deficiency48,49. This particular deficiency is considered a risk factor for cognitive 
decline51 and indicative of a poor nutritional intake48,49. It is also linked to raised 
homocysteine levels, which are associated with an increased risk for coronary heart 
disease, stroke and dementia52,53 and to physical and functional decline54.  
Unknown anaemia 
It is unclear whether the category ‘unknown anaemia’ represents one specific aetiology or 
a collection of several mechanisms40. Many possible underlying processes have been 
linked to or suggested for unknown anaemia in the elderly, including a blunted 
erythropoietic response21,55-57, low levels of inflammatory markers21,56,58, decreased 
androgen levels58, decreased haematopoiesis56,59-61, unrecognised renal disease56,58, and 
undiagnosed or early myelodysplasia58,59. Despite extensive diagnostics, the proportion of 
unknown anaemia remains high in virtually all study populations. Adding a comprehensive 
haematologic evaluation does not lower this proportion62.  
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Impact of anaemia on morbidity and mortality 
Morbidity 
Anaemia is associated with a long list of complications and increased risks for underlying 
conditions. An overview can be found in Figure 4. 
  
Figure 4, An overview of the negative effects on health associated with anaemia44,63-76.  
A decrease in quality of life has been observed in anaemic patients, which may be due to 
decreased mobility77, fatigue, changing cognitive function, depression or decreased 
muscle strength44. The association has been observed in patients diagnosed with 
malignancies78,79  and chronic renal insufficiency78,80 but also in a population of 
community-dwelling elderly81. 
The association of anaemia with these detrimental effects were observed in populations 
presenting with all levels of anaemia, from mild (Hb ≥ 10.0 g/dL) to severe (Hb < 8.0 g/dL). 
It could be reasoned that a more dramatically decreased Hb level will lead to more severe 
complaints and therefore the negative associations of anaemia would be mostly due to 
the severe cases. However, this is contradicted by studies including only patients 
presenting with mild anaemia. Mild anaemia was found to be associated with worse 
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selective attention performance and disease-specific quality of life ratings, poorer physical 
performance and functional ability, decreased muscular strength, increased frailty risk, 
increased risk of physical decline, recurrent falls69,74,81-84, significant decline in quality of 
life81, impaired cognition71, and increased risk for depression and dementia81,85. 
Mortality 
Anaemia is associated with increased all-cause mortality risk in a variety of patient 
cohorts. A higher risk was observed in anaemic patients diagnosed with cardiovascular 
diseases64,86-90, malignancies91, and patients undergoing haemodialysis92,93. Patients living 
in a nursing home78,94 and the community-dwelling older population (≥ 65 years) also 
displayed an increased mortality risk when anaemic65,66,84,95,96. Again, these observations 
are not solely due to severe anaemia. Mild anaemia was associated with an increased risk 
of all-cause mortality in both the elderly (≥ 65 years)97 and hospitalised heart failure 
patients98.  
A significantly increased mortality was also established in a disease-free population. This 
suggests that the observed effect of anaemia on mortality is, at least in part, independent 
of chronic or acute disease status65.  
Digital microscopy 
Laboratory techniques are vital in determining the underlying aetiology of anaemia. The 
peripheral blood smear remains an important part of the laboratory diagnostics used for 
anaemia evalution99. Manual morphological assessment of this smear has been the gold 
standard for years but comes with several pitfalls. It is labour intensive, requires highly 
and continuously trained personnel and may be vulnerable to inter-observer variability. 
Digital microscopy (DM) systems have been in development for several decades and the 
technology has now advanced to the stage where these systems may be considered as 
reliable substitutes for manual assessment100-106. So far, the technology has mainly 
focused on the classification of leukocytes. Analysing these cells plays an important role in 
detecting a bone marrow disease. Anaemia is often the first symptom or sign of such a 
disease, making assessment of leukocytes on the peripheral blood smear a relevant step in 
anaemia analysis.  
Figure 5 (opposite page), Overview of the workflow of the digital microscope (DM). After a 
peripheral blood smear has been produced, it is offered to the DM which classifies the 
ordered number of blood cells. The system is capable of recognising a wide variety of cells. 
The examples in this figure include A) lymphocytes of a patient diagnosed with chronic 
lymphatic leukaemia (CLL) B) blast cells and C) tear drop cells. 
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Several automated morphological systems have been developed by various manufacturers 
since the 1970s, aided by the increasing possibilities of cameras, software and 
computers107. The DM consists of a slide scanning unit and a computer running the 
necessary software. The system uses a number of advanced mathematical algorithms to 
classify leukocytes in peripheral blood smears. Using over 250 parameters, this artificial 
neural network classifies each cell into one of the 11 cell classes that the system is 
currently capable of detecting. The parameters include shape-features, colour-features, 
texture-features and special features designed to capture morphological aspects of the 
cell such as the nucleolus or edge basophilia. This standard set of criteria is predefined by 
the manufacturer and cannot be altered by the operator. DM systems are capable of 
classifying 200 white blood cells within 2.5 minutes. The software then displays the 
analysed cells according to their class (e.g. neutrophils or blast cells). An operator will 
review the results and, if necessary, correct them before releasing the data to the 
laboratory information system. An overview of the workflow can be found in Figure 5.  
Manual morphological assessment remains the current gold standard for the analysis of a 
peripheral blood smear. The validation of DM systems against this gold standard has been 
ongoing for the past decade. It has been shown that the classification performance of the 
DM is equal to manual assessment when classifying the main peripheral blood cell classes: 
neutrophils, lymphocytes, monocytes, eosinophils, and basophils. The detection of blast 
cells, essential for the correct and early diagnosis of haematological malignancies, also 
proved to be accurate100-106. Development of the technology for the classification of other 
cell types besides leukocytes is ongoing. DM systems can also classify erythrocytes in the 
peripheral blood smear108 and nucleated cells in body fluids (cerebrospinal fluid, 
abdominal fluid and continuous ambulant peritoneal dialysis fluid)109. This is another step 
towards a completely automated differential of leukocytes, erythrocytes, and 
thrombocytes in peripheral blood, body fluids and bone marrow aspirate.   
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Scope of the thesis 
The first part of this thesis discusses anaemia in general practice. The prevalence of the 
different aetiology of anaemia remains elusive. To remedy this, we analysed a large 
database of general practice patients newly diagnosed with anaemia. This database 
allowed for detailed study of the prevalence of a wide range of causes of anaemia. In 
addition, it supported a thorough discussion of the value of MCV in the evaluation of 
anaemia in general practice (Chapter 2). A detailed analysis of the impact of the different 
causes on mortality risk of anaemic general practice patients was performed. This was 
combined with determining the standardised mortality ratio of all-cause anaemia per five-
year age group in order to demonstrate the relevance of anaemia evaluation (Chapter 3). 
Patients with macrocytic anaemia are rarely described in literature. Our population-based 
database allowed for a detailed description of the largest macrocytic cohort to date. The 
prevalence of different aetiology was determined and the impact of these causes on 
mortality risk was evaluated (Chapter 4). Lastly an analysis of the adherence of GPs to the 
current guidelines regarding the diagnostics and treatment of ACD and IDA was conducted 
(Chapter 5 and 6). This analysis also included the mortality risk associated with the non-
application of these guidelines. These five studies comprise the first part of the thesis. 
Morphological assessment of the peripheral blood smear is often part of anaemia 
evaluation, especially when a bone marrow disease is considered as the underlying cause. 
The second part of this thesis describes two steps of the validation process of DM systems, 
which allow for the automated and standardised assessment of peripheral blood smears. 
The inter-laboratory reproducibility between four DM systems was studied (Chapter 7), 
followed by a detailed analysis of a large leukocyte database, consisting of 1.4 million cells. 
This database was used to determine the accuracy of DM systems for a wide range of 
leukocyte classes, compared to manual morphological assessment, the current gold 
standard (Chapter 8). 
This thesis provides reliable prevalence rates of a wide range of possible causes of 
anaemia and details their impact on mortality risks. More information on these topics will 
hopefully bring a greater awareness of the potential danger of anaemia to a patient. In 
addition, two steps in the validation of DM systems for use in routine practice are 
described. The implementation of these systems will allow for a standardised and 
automated differential in diagnostic laboratories.  
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Abstract 
Background: Anaemia is a common finding in general practice, but despite its marked 
prevalence, little data is available on the prevalence of the underlying causes. To 
determine the cause of anaemia, many physicians rely on the mean corpuscular volume 
(MCV) to guide further diagnostic testing. However, the exact value of MCV in general 
practice is unclear.   
Methods: From the 1st of February 2007 until the 1st of February 2013, patients aged 50 
years or older and presenting with a newly discovered anaemia to their general 
practitioner, were prospectively studied. Anaemia was defined as haemoglobin level 
below 13.7 g/dL in men and below 12.1 g/dL in women. A wide range of laboratory 
parameters was determined. Two independent observers established the cause or causes 
of anaemia, based on these parameters.  
Results: A cause of anaemia could be established in 1810 (72.0%) of the 2513 included 
patients. Anaemia of chronic disease (29.8%), iron deficiency (18.7%) and renal anaemia 
(12.3%) were the most common causes. Other causes included haemoglobinopathy (0.6%) 
and vitamin B12 deficiency (4.2%). Strictly following the classical division of the different 
causes over the MCV-based classes found 28.8% of causes in the incorrect class.   
Conclusion: The predictive value of MCV is not strong enough to justify excluding causes of 
anaemia based solely on this parameter. Existing MCV-based algorithms used for the 
clarification of the cause of anaemia should be reconsidered.  
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Introduction 
Anaemia is a common finding in general practice. The prevalence of anaemia in a 
community-dwelling population increases from about 5% in the age group 50-64, to over 
20% in people aged 85 years and older1. In a sample population of 65 years and older, the 
incidence of anaemia was found to be 12.8/1000 person-years (95% CI 9.4-17.2) in men 
and 10.9/1000 person years (95% CI 7.8-14.9) in women2. The majority of patients 
presents with a mild grade anaemia (Hb ≥ 10.0 g/dL)
3,4.  
For many years, anaemia in the elderly was believed to be a normal consequence of 
aging1,5. However, anaemia has been shown to be associated with functional decline5, 
frailty5, increased mortality1,6,7, increased morbidity6,7 and decreased quality of life7,8. In 
the elderly (> 65 years), anaemia reflects both poor health and increased vulnerability to 
poor outcomes5,9,10, such as longer and more frequent hospital stays7,11-13. These 
consequences are not solely associated with severe anaemia. Mild anaemia is also 
associated with an increased risk of hospitalisation and all-cause mortality14. The presence 
of anaemia was established as an independent predictor of survival, after adjustment for 
age, gender, race and chronic medical conditions5,15.  
Despite anaemia being such a frequently encountered clinical finding, information 
regarding the prevalence of the underlying causes is surprisingly scarce. Several studies on 
anaemia aetiology in the general population have been published, but in general these 
included relatively small patient numbers and provided a limited analysis of underlying 
causes1-3,5,16-20.  
The hallmark diagnostic algorithm for the evaluation of anaemia is based on the mean 
corpuscular volume (MCV) and encompasses an initial classification of anaemia as being 
microcytic, normocytic or macrocytic, with a specific set of causes listed for each class. 
However, the validity of this algorithm has, to the best of our knowledge, not yet been 
evaluated in general practice. 
In this large prospective cohort study, we systematically investigated a wide range of 
underlying causes of anaemia in patients presenting to their general practitioner (GP). We 
provide reliable prevalence rates for these causes and analyse their distribution over age 
groups, gender, classes and types of anaemia. Furthermore, we discuss both the validity 
and the shortcomings of the MCV-based diagnostic algorithm.  
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Material and methods 
Patient inclusion 
This study was approved by the ethics committee of the Albert Schweitzer Hospital and 
included on community-dwelling men and women aged 50 years or older. These patients 
presented to a participating general practitioner with symptoms indicative of anaemia. In 
case laboratory measurements established a newly diagnosed anaemia (i.e. no known 
anaemia  in the preceding two years, according to the laboratory information system) the 
patient was included in the study cohort and a standardised laboratory work-up was 
immediately performed. The inclusion period lasted from the 1st of February 2007 until 
the 1st of February 2013. The follow-up period ended on the 1st of September 2013. 
Anaemia was defined as haemoglobin (Hb) level below 13.7 g/dL (8.5 mmol/L, men) and 
below 12.1 g/dL (7.5 mmol/L, women). These haemoglobin levels constitute the cut-off 
values used by general practitioners in the Netherlands, as recommended by the Dutch 
College of General Practitioners (DCGP)22. 
Laboratory work-up 
For each patient, a standardised laboratory work-up was performed, which allowed for 
the consideration of a broad range of causes. The following parameters were included: 
haemoglobin, MCV, erythrocytes, erythrocyte sedimentation rate, reticulocytes, 
thrombocytes, leukocytes, ferritin, transferrin, serum iron, serum vitamin B12, serum folic 
acid, lactate dehydrogenase (LDH), creatinin and C-reactive protein (CRP). At the 
discretion of the general practitioner, patients were referred to the hospital for a 
consultation with a medical specialist and, if necessary, additional diagnostic 
examinations. For these referred patients, a hospital chart review was conducted.  
Classification of causes of anaemia 
A classification system was developed, which included the following causes: 1) anaemia of 
chronic disease (ACD), 2) haemoglobinopathy, 3) haemolysis, 4) possible bone marrow 
disease, 5) iron deficiency (IDA), 6) vitamin B12 deficiency, 7) folic acid deficiency, 8) renal 
anaemia, and 9) other causes (see Table 1 for the definition of each cause). When no 
cause could be determined, it was classified as unknown. This system was based on the 
DCGP guideline23 in use at the time of the study and on the knowledge of an experienced 
clinical chemist (JR) and internist (ML). 
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Cause Definition 
1) Anaemia of chronic 
disease 
Ferritin > 100 μg/L, Transferrin < 2.0 g/L and/or iron < 14 μmol/L 
(men), < 10 μmol/L (women) 
2) Haemoglobinopathy Confirmed by DNA testing 
3) Haemolysis LDH > 450 U/L, Reticulocytes > 2.5%, Bilirubin > 17 μmol/L 
4) Possible bone marrow 
disease 
Abnormal number leukocytes and thrombocytes 
Reticulocytes < 2.5% 
5) Iron deficiency anaemia Ferritin < 25 μg/L (men), < 20 μg/L (women) 
6) Vitamin B12 deficiency Serum vitamin B12 < 130 pmol/L 
7) Folic acid deficiency Serum folic acid < 5 nmol/L 
8) Renal anaemia Estimated creatinin clearance (MDRD) ≤ 45 mL/min/1.73 m2 21 
9) Other Reported by treating physician 
10) Unknown No cause could be determined 
 Table 1, Definitions of the different causes. The cut-off values were derived from the 
reference intervals used in the Clinical Chemistry laboratory of the Albert Schweitzer 
Hospital where all tests were conducted. 
If a case classified as renal anaemia also displayed features of ACD, this case was classified 
as renal anaemia. ACD was only classified as a separate cause in these cases, if there was a 
clear indication of a concurrent infection or chronic disease. The cause of anaemia was 
established by two independent observers (KS and ML). In case of a discrepancy, the 
observers deliberated until a consensus was reached.  
Definition age groups, class anaemia and type anaemia 
The population was divided into four age groups: 50-64 years, 65-74 years, 75-84 years 
and 85+ years1. Cases were divided into three classes: microcytic (MCV < 80 fL), 
normocytic (MCV 80-100 fL) and macrocytic (MCV > 100 fL) anaemia8,23 ; and into the 
types mild (Hb ≥ 10.0 g/dL), moderate (Hb 8.0-9.9 g/dL) and severe (Hb < 8.0 g/dL) 
anaemia3.  
Statistics 
Continuous variables were described using medians, ranges and interquartile ranges (IQR), 
and categorical variables were described using percentages. Fisher’s exact tests were used 
to determine the association between cause and type of anaemia, class of anaemia, age 
group and gender. The association between cause and age - expressed as a continuous 
variable- was assessed using Mann-Whitney tests, which compared the age distribution of 
patients diagnosed with a certain cause to the age distribution of the residual cohort. The 
95% binomial proportion confidence intervals of sensitivity and specificity were calculated 
according to the Wilson score method.  
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The statistical tests were performed separately for each cause, which made it necessary to 
correct for multiple testing. Results for type, class and age group were considered 
significant when the two-sided P-values were below the Bonferroni-adjusted significance 
level of 0.005.  Calculations were performed using Statistical Package for Social Sciences 
(SPSS) version 18 for Windows. 
 
Figure 1, Frequency of the different causes of anaemia and an overview of the frequency of 
each established cause divided per gender. The absolute numbers are noted above the 
bars. Percentages may be found in supplemental Table 1.   
Results 
Patient characteristics 
In a six year time period, a total of 2513 patients aged 50 years or older were included in 
the study, 1238 (49.3%) men and 1275 (50.7%) women. Men had a median age of 72 years 
(range 50-101) at the time of inclusion, women a median age of 77 years (range 50-103). 
An overview of patient characteristics is provided in Table 2.  
 
 
Chapter 2 
 
 34 
Cause Definition 
1) Anaemia of chronic 
disease 
Ferritin > 100 μg/L, Transferrin < 2.0 g/L and/or iron < 14 μmol/L 
(men), < 10 μmol/L (women) 
2) Haemoglobinopathy Confirmed by DNA testing 
3) Haemolysis LDH > 450 U/L, Reticulocytes > 2.5%, Bilirubin > 17 μmol/L 
4) Possible bone marrow 
disease 
Abnormal number leukocytes and thrombocytes 
Reticulocytes < 2.5% 
5) Iron deficiency anaemia Ferritin < 25 μg/L (men), < 20 μg/L (women) 
6) Vitamin B12 deficiency Serum vitamin B12 < 130 pmol/L 
7) Folic acid deficiency Serum folic acid < 5 nmol/L 
8) Renal anaemia Estimated creatinin clearance (MDRD) ≤ 45 mL/min/1.73 m2 21 
9) Other Reported by treating physician 
10) Unknown No cause could be determined 
 Table 1, Definitions of the different causes. The cut-off values were derived from the 
reference intervals used in the Clinical Chemistry laboratory of the Albert Schweitzer 
Hospital where all tests were conducted. 
If a case classified as renal anaemia also displayed features of ACD, this case was classified 
as renal anaemia. ACD was only classified as a separate cause in these cases, if there was a 
clear indication of a concurrent infection or chronic disease. The cause of anaemia was 
established by two independent observers (KS and ML). In case of a discrepancy, the 
observers deliberated until a consensus was reached.  
Definition age groups, class anaemia and type anaemia 
The population was divided into four age groups: 50-64 years, 65-74 years, 75-84 years 
and 85+ years1. Cases were divided into three classes: microcytic (MCV < 80 fL), 
normocytic (MCV 80-100 fL) and macrocytic (MCV > 100 fL) anaemia8,23 ; and into the 
types mild (Hb ≥ 10.0 g/dL), moderate (Hb 8.0-9.9 g/dL) and severe (Hb < 8.0 g/dL) 
anaemia3.  
Statistics 
Continuous variables were described using medians, ranges and interquartile ranges (IQR), 
and categorical variables were described using percentages. Fisher’s exact tests were used 
to determine the association between cause and type of anaemia, class of anaemia, age 
group and gender. The association between cause and age - expressed as a continuous 
variable- was assessed using Mann-Whitney tests, which compared the age distribution of 
patients diagnosed with a certain cause to the age distribution of the residual cohort. The 
95% binomial proportion confidence intervals of sensitivity and specificity were calculated 
according to the Wilson score method.  
Relevance of MCV 
 
 35 
The statistical tests were performed separately for each cause, which made it necessary to 
correct for multiple testing. Results for type, class and age group were considered 
significant when the two-sided P-values were below the Bonferroni-adjusted significance 
level of 0.005.  Calculations were performed using Statistical Package for Social Sciences 
(SPSS) version 18 for Windows. 
 
Figure 1, Frequency of the different causes of anaemia and an overview of the frequency of 
each established cause divided per gender. The absolute numbers are noted above the 
bars. Percentages may be found in supplemental Table 1.   
Results 
Patient characteristics 
In a six year time period, a total of 2513 patients aged 50 years or older were included in 
the study, 1238 (49.3%) men and 1275 (50.7%) women. Men had a median age of 72 years 
(range 50-101) at the time of inclusion, women a median age of 77 years (range 50-103). 
An overview of patient characteristics is provided in Table 2.  
 
 
Chapter 2 
 
 36 
Causes 
Of the 2513 patients included in the study, 2284 patients (90.8%) presented with a single 
or unknown cause for their anaemia. A double cause was found in 211 patients (8.4%), a 
triple cause in 14 patients (0.6%) and a quadruple cause in 4 patients (0.2%). A total of 
2764 causes, including unknown anaemia, were found in this population. ACD was found 
823 times (29.8%), iron deficiency 516 times (18.7%) and renal anaemia 340 times 
(12.3%). Possible bone marrow disease (3.8%), vitamin B12 deficiency (4.2%) and ‘other 
causes’ (3.8%), were also found regularly (Figure 1). The cause remained unknown in 703 
patients (25.4%). For a complete overview of the distribution of the causes of gender, 
class, age group, and type, please refer to supplemental Tables 1-4. ACD was found more 
often among men than women (P < 0.001), while iron deficiency and renal anaemia were 
more common in women (P < 0.001 and P = 0.001 respectively) (Figure 1). 
Parameters Median: IQR Reference values  
Age 
- Men 
- Women 
75 years: 64-83 
72 years: 63-81 
77 years: 65-85 
 
Hemoglobin 
- Men  
- Women 
11.8 g/dL: 11.0-12.9 
12.9 g/dL: 11.9-13.4 
11.3 g/dL: 10.5-11.8 
 
13.7-17.7 g/dL 
12.1-16.1 g/dL 
MCV 90 fL: 86-94  81-99 fL 
Erythrocytes 
- Men 
- Women 
4.0 10^12/L: 3.7-4.2 
4.2 10^12/L: 3.9-4.4 
3.9 10^12/L: 3.6-4.0 
 
4.6-6.2 10^12/L 
4.2-5.4 10^12/L 
Reticulocytes 1.0 %: 0.8-1.3 < 2.5% 
Thrombocytes 272 10^9/L: 218-349 150-400 10^9/L 
Leukocytes 7.0 10^9/L: 5.7-9.0 4.3-10.0 10^9/L 
Ferritin 
- Men 
- Women 
125 μg/L: 38-274 
161 μg/L: 64-334 
85 μg/L: 22-226 
 
25-250 μg/L 
20-150 μg/L 
Transferrin 2.4 g/L: 2.0-2.8 2.0-3.6 g/L 
Iron 
- Men 
- Women 
9.3 μmol/L: 5.9-13.8 
10.8 μmol/L: 6.1-15.3 
8.4 μmol/L: 4.3-12.2 
 
14-28 μmol/L 
10-25 μmol/L 
LDH 344 U/L: 300-405 < 450 U/L 
Table 2, Patient characteristics of the study population.The reference values constitute the 
values used in the Clinical Chemistry laboratory of the Albert Schweitzer Hospital, where all 
tests were conducted.  
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Age and anaemia type 
The number of patients in age groups 50-64, 65-74, 75-84 and 85+ were 651 (25.9%), 578 
(23.0%), 745 (29.6%) and 539 (21.4%), respectively (Figure 2-A-D).  
The relative prevalence of renal anaemia rose significantly with every age group, from 
2.4% in age group 50-64 to 24.4% in age group 85+ (P < 0.001 for each comparison). 
Median age of patients with renal anaemia was 83.0 years (N = 340, IQR = 76.0-87.0) 
compared to a median age of 73 years (N = 2173, IQR = 62.5-82.0) of the rest of the cohort 
(P < 0.001). 
Both haemoglobinopathy and iron deficiency were established more often in age group 
50-64 compared to 65-74 (P = 0.039 and < 0.001), 75-84 (P = 0.005 and < 0.001) and 85+ (P 
= 0.001 and < 0.001). Median age for iron deficiency was 70.5 years (N = 516, IQR = 58.0-
81.0) compared to a median age of 76.0 years (N = 1997, IQR = 65.0-84.0) for the residual 
cohort (P < 0.001). For patients diagnosed with haemoglobinopathy, the median age was 
60.0 years (N = 17, IQR = 55.0-68.5) compared to a median age of 75.0 years (N = 2496, 
IQR = 64.0-83.0) of the residual cohort (P <0.001).  
  
Figure 2, Distribution of causes over the four age groups. Percentages and absolute 
numbers may be found in supplemental Table 2. A) 50-64 years (700 causes) B) 65-74 years 
(624 causes) C) 75-84 years (841 causes) and D) 85+ years (599 causes).  
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Causes 
Of the 2513 patients included in the study, 2284 patients (90.8%) presented with a single 
or unknown cause for their anaemia. A double cause was found in 211 patients (8.4%), a 
triple cause in 14 patients (0.6%) and a quadruple cause in 4 patients (0.2%). A total of 
2764 causes, including unknown anaemia, were found in this population. ACD was found 
823 times (29.8%), iron deficiency 516 times (18.7%) and renal anaemia 340 times 
(12.3%). Possible bone marrow disease (3.8%), vitamin B12 deficiency (4.2%) and ‘other 
causes’ (3.8%), were also found regularly (Figure 1). The cause remained unknown in 703 
patients (25.4%). For a complete overview of the distribution of the causes of gender, 
class, age group, and type, please refer to supplemental Tables 1-4. ACD was found more 
often among men than women (P < 0.001), while iron deficiency and renal anaemia were 
more common in women (P < 0.001 and P = 0.001 respectively) (Figure 1). 
Parameters Median: IQR Reference values  
Age 
- Men 
- Women 
75 years: 64-83 
72 years: 63-81 
77 years: 65-85 
 
Hemoglobin 
- Men  
- Women 
11.8 g/dL: 11.0-12.9 
12.9 g/dL: 11.9-13.4 
11.3 g/dL: 10.5-11.8 
 
13.7-17.7 g/dL 
12.1-16.1 g/dL 
MCV 90 fL: 86-94  81-99 fL 
Erythrocytes 
- Men 
- Women 
4.0 10^12/L: 3.7-4.2 
4.2 10^12/L: 3.9-4.4 
3.9 10^12/L: 3.6-4.0 
 
4.6-6.2 10^12/L 
4.2-5.4 10^12/L 
Reticulocytes 1.0 %: 0.8-1.3 < 2.5% 
Thrombocytes 272 10^9/L: 218-349 150-400 10^9/L 
Leukocytes 7.0 10^9/L: 5.7-9.0 4.3-10.0 10^9/L 
Ferritin 
- Men 
- Women 
125 μg/L: 38-274 
161 μg/L: 64-334 
85 μg/L: 22-226 
 
25-250 μg/L 
20-150 μg/L 
Transferrin 2.4 g/L: 2.0-2.8 2.0-3.6 g/L 
Iron 
- Men 
- Women 
9.3 μmol/L: 5.9-13.8 
10.8 μmol/L: 6.1-15.3 
8.4 μmol/L: 4.3-12.2 
 
14-28 μmol/L 
10-25 μmol/L 
LDH 344 U/L: 300-405 < 450 U/L 
Table 2, Patient characteristics of the study population.The reference values constitute the 
values used in the Clinical Chemistry laboratory of the Albert Schweitzer Hospital, where all 
tests were conducted.  
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Mild anaemia was found in a majority of 2224 patients (88.5%), moderate anaemia in 198 
patients (7.9%) and severe anaemia in 91 patients (3.6%) (Figure 3- A-C). Both ACD and an 
unknown cause were found more often in patients with a mild anaemia (31.8% and 
28.1%), compared to those with moderate (20.7% and 6.5%, P = 0.015 and P < 0.001) or 
severe (6.3% and 0%, both P < 0.001) anaemia. Iron deficiency was found more often in 
the cohort with severe anaemia (61.3%), compared to both the mild and moderate 
anaemia cohorts (14.6% and 39.4%, both P < 0.001).  
 
Figure 3, Distribution of causes over the three types of anaemia. Percentages and absolute 
numbers may be found in supplemental Table 3. A) mild anaemia (Hb ≥ 10.0 g/dL, 2407 
causes) B) moderate anaemia (Hb 8.0-9.9 g/dL, 246 causes) and C) severe anaemia (Hb < 
8.0 g/dL, 111 causes).  
Anaemia class 
Microcytic anaemia was found in 250 patients (9.9%), normocytic anaemia in 2107 
patients (83.8%) and macrocytic anaemia in 156 patients (6.2%). Iron deficiency and 
haemoglobinopathy were more prevalent in patients presenting with a microcytic 
anaemia compared to both normocytic (both P < 0.001) and macrocytic (both P < 0.001) 
anaemia. ACD and an unknown cause were more frequent in patients presenting with 
normocytic anaemia as compared to both microcytic (both P < 0.001) and macrocytic 
(both P < 0.001) anaemia.  
Haemolysis, possible bone marrow disease, vitamin B12 deficiency, folic acid deficiency 
and other causes can be found more often in macrocytic anaemia, compared to both 
microcytic (P < 0.001-0.021) and normocytic (all P < 0.001) anaemia.  
Strictly following these statistical findings and classifying iron deficiency and 
haemoglobinopathy as microcytic, ACD and unknown as normocytic, and haemolysis, 
possible bone marrow disease, vitamin B12 deficiency, folic acid deficiency and other 
causes as macrocytic, meant that 28.8% of the causes were found in the incorrect class 
and 71.2% in the correct class. The relative prevalence of a cause in an incorrect class may 
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be small (0.3% for haemolysis within microcytic anaemia) or quite large (20.9% for ACD 
within macrocytic anaemia), but each cause, except haemoglobinopathy, could be found 
in each class of anaemia (Figure 4-A-C).  
 
Figure 4, Distribution of causes over the three class of anaemia. Percentages and absolute 
numbers may be found in supplemental Table 4. A) microcytic anaemia (MCV < 80 fL) B) 
normocytic anaemia (MCV 80-100 fL) and C) macrocytic anaemia (MCV > 100 fL).  
To further analyse the reliability of MCV for excluding causes, sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) of the MCV class were 
calculated per established cause (Table 3). Renal anaemia was excluded from these 
calculations since our data did not establish a specific class for this cause. The causes as 
determined by the experts were considered the reference standard. For ACD, for example, 
patients presenting with ACD and normocytic anaemia were considered true positives, 
patients presenting with no ACD and normocytic anaemia were considered false positives, 
patients presenting with ACD and microcytic or macrocytic anaemia were considered false 
negatives, and patients presenting with no ACD and microcytic or macrocytic anaemia 
were considered true negatives.  
For six causes, including the category unknown, the NPVs are considered too low to be 
able to use MCV as a reliable exclusionary parameter (Table 3). In addition, several causes 
show either a low sensitivity or specificity for MCV. The high NPV for haemoglobinopathy, 
haemolysis and folic acid deficiency does allow MCV to function as an exclusionary value 
for these causes.  
Discussion 
Several studies analysing causes of anaemia in general practice have been published1-3,5,16-
20, but the majority of these included only a small number of patients with anaemia. To 
the best of our knowledge, the cohort of anaemia patients in general practice described in 
this study is the largest  
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be small (0.3% for haemolysis within microcytic anaemia) or quite large (20.9% for ACD 
within macrocytic anaemia), but each cause, except haemoglobinopathy, could be found 
in each class of anaemia (Figure 4-A-C).  
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calculations since our data did not establish a specific class for this cause. The causes as 
determined by the experts were considered the reference standard. For ACD, for example, 
patients presenting with ACD and normocytic anaemia were considered true positives, 
patients presenting with no ACD and normocytic anaemia were considered false positives, 
patients presenting with ACD and microcytic or macrocytic anaemia were considered false 
negatives, and patients presenting with no ACD and microcytic or macrocytic anaemia 
were considered true negatives.  
For six causes, including the category unknown, the NPVs are considered too low to be 
able to use MCV as a reliable exclusionary parameter (Table 3). In addition, several causes 
show either a low sensitivity or specificity for MCV. The high NPV for haemoglobinopathy, 
haemolysis and folic acid deficiency does allow MCV to function as an exclusionary value 
for these causes.  
Discussion 
Several studies analysing causes of anaemia in general practice have been published1-3,5,16-
20, but the majority of these included only a small number of patients with anaemia. To 
the best of our knowledge, the cohort of anaemia patients in general practice described in 
this study is the largest  
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Cause MCV class Sen 95% CI Spec 95% CI PPV NPV 
Anaemia of chronic disease Normocytic 92.7 90.7-94.3 20.5 18.6-22.5 36.2 85.2 
Haemoglobinopathy Microcytic 94.1 73.0-99.0 90.6 89.4-91.7 6.4 99.9 
Haemolysis Macrocytic 37.5 18.5-61.4 93.9 92.0-94.8 3.8 99.6 
Possible bone marrow disease Macrocytic 16.2 10.4-24.4 94.2 93.2-95.1 10.9 96.3 
Iron deficiency anaemia Microcytic 37.2 33.2-41.5 97.1 96.3-97.8 76.8 85.6 
Vitamin B12 deficiency Macrocytic 22.6 15.9-31.1 94.5 93.6-95.4 16.7 96.2 
Folic acid deficiency Macrocytic 34.8 18.8-55.1 94.1 93.1-94.9 5.1 99.3 
Other Macrocytic 26.4 19.0-35.5 94.7 93.7-95.5 17.9 96.7 
Unknown Normocytic 95.4 93.6-96.8 20.7 18.9-22.6 31.8 92.1 
Table 3, Statistical analysis of the reliability of MCV when excluding causes of anaemia. 
Sensitivity (Sen) and specificity (Spec) (with corresponding confidence intervals (CI)), 
positive predictive value (PPV) and negative predictive value (NPV) for each cause and 
corresponding class. Renal anaemia is not included in this table since statistical analysis 
did not show a decisive class for this cause. 
cohort analysed to date. Analysis of this cohort showed that the predictive value of MCV is 
not strong enough to justify using it as an exclusionary parameter.  
 
Anaemia class 
For decades, a specific set of causes has been attributed to microcytic, normocytic and 
macrocytic anaemia. Statistical testing on our data showed a division that generally 
followed the traditional grouping of causes according to MCV (i.e. iron deficiency and 
haemoglobinopathy are microcytic; ACD and unknown are normocytic; haemolysis, 
possible bone marrow disease, vitamin B12 deficiency, folic acid deficiency and other 
causes are macrocytic). Strictly adhering to this division resulted in 28.8% of causes found 
in the incorrect class. This observation may be partly explained by patients presenting 
with multiple causes, which were associated with different classes. For example, a patient 
may present with both iron and folic acid deficiency. Modern cell counters give an average 
when reporting MCV, so the combined microcytic (due to iron deficiency) and macrocytic 
(due to folic acid deficiency) erythrocytes will lead to a normocytic MCV value when 
measured.  
Strict limits were used to establish the different nutrient deficiencies. However, for both 
vitamin B12 and folic acid deficiency, the values measured just above these limits (130-
200 pmol/L for vitamin B12 and 5-10 nmol/L for folic acid) do not necessarily exclude a 
deficiency. Cases such as ACD, unknown and IDA in the macrocytic cohort, may have had 
an underlying vitamin B12 or folic acid deficiency, which remained undetected due to 
these strict limits. We may also have missed cases of IDA due to the difficulty of 
distinguishing between ACD and IDA when the ferritin value lies in the grey area. A serum 
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ferritin level ranging between 20(♀)/25(♂)-100 µg/L may be present in both causes. The 
criteria used in this study did not allow for the distinction between ACD and IDA when the 
ferritin level was found to be within this range. Cases such as vitamin B12 deficiency, folic 
acid deficiency and unknown in the microcytic cohort may have had an underlying iron 
deficiency that went unnoticed due to the set limits.  
Earlier studies found the diagnostic accuracy of MCV insufficient in hospitalised 
patients24,25. Our results strongly suggest that MCV is not reliable enough to be able to 
exclude causes based on this value alone, when evaluating anaemia in general practice. In 
practice, physicians may start analysis of a potentially anaemic patient by determining the 
haemoglobin and MCV level, and if anaemia is established, they may be led by the MCV 
when deciding on further diagnostic testing. Strictly following MCV-based algorithms may 
result in an incorrect or incomplete diagnosis of the underlying cause or causes of 
anaemia.  
Anaemia type and gender 
ACD and an unknown cause for anaemia were shown to be associated with mild anaemia, 
as has been observed before1,5. For ACD, this association may be explained by the 
underlying disturbance of iron homeostasis in these patients, leading to retention of iron 
within the reticuloendothelial system26. This limits the availability of iron for the 
production of erythrocytes but does not completely abolish their production, resulting in a 
mild anaemia. Since the underlying aetiology of unknown anaemia is unclear, the 
association with mild anaemia is difficult to explain. It is possible  that physicians are more 
reluctant to look for the underlying cause if a patient presents with mild anaemia 
compared to a patient presenting with moderate or severe anaemia. The severe anaemia 
cohort did not show any case of unknown anaemia. General practitioners responded to 
such a low haemoglobin level with a quick, sometimes immediate, referral to the hospital 
where the underlying cause was elucidated and consequently treated. 
By far the most prevalent cause in the severe anaemia cohort was iron deficiency. This 
may be explained by the association of iron deficiency with occult blood loss. This loss 
often happens gradually and goes unnoticed for a long time. This allows the level to 
become severe before a patient visits his or her general practitioner, due to anaemia 
symptoms such as fatigue.  
Shavelle et al (2012)5 described a cohort similar to ours (≥ 50 years, non-institutionalised 
population). However, they only considered the main causes of anaemia. Their study 
showed a comparable prevalence for ACD (26% vs. 29.8%), nutrient deficiency (24% vs. 
23.7%) and renal anaemia (11% vs. 12.3%), but did show a much higher prevalence for 
unknown anaemia (39% vs. 25.4%). This difference may be explained by the inclusion of 
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Cause MCV class Sen 95% CI Spec 95% CI PPV NPV 
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Table 3, Statistical analysis of the reliability of MCV when excluding causes of anaemia. 
Sensitivity (Sen) and specificity (Spec) (with corresponding confidence intervals (CI)), 
positive predictive value (PPV) and negative predictive value (NPV) for each cause and 
corresponding class. Renal anaemia is not included in this table since statistical analysis 
did not show a decisive class for this cause. 
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causes are macrocytic). Strictly adhering to this division resulted in 28.8% of causes found 
in the incorrect class. This observation may be partly explained by patients presenting 
with multiple causes, which were associated with different classes. For example, a patient 
may present with both iron and folic acid deficiency. Modern cell counters give an average 
when reporting MCV, so the combined microcytic (due to iron deficiency) and macrocytic 
(due to folic acid deficiency) erythrocytes will lead to a normocytic MCV value when 
measured.  
Strict limits were used to establish the different nutrient deficiencies. However, for both 
vitamin B12 and folic acid deficiency, the values measured just above these limits (130-
200 pmol/L for vitamin B12 and 5-10 nmol/L for folic acid) do not necessarily exclude a 
deficiency. Cases such as ACD, unknown and IDA in the macrocytic cohort, may have had 
an underlying vitamin B12 or folic acid deficiency, which remained undetected due to 
these strict limits. We may also have missed cases of IDA due to the difficulty of 
distinguishing between ACD and IDA when the ferritin value lies in the grey area. A serum 
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ferritin level ranging between 20(♀)/25(♂)-100 µg/L may be present in both causes. The 
criteria used in this study did not allow for the distinction between ACD and IDA when the 
ferritin level was found to be within this range. Cases such as vitamin B12 deficiency, folic 
acid deficiency and unknown in the microcytic cohort may have had an underlying iron 
deficiency that went unnoticed due to the set limits.  
Earlier studies found the diagnostic accuracy of MCV insufficient in hospitalised 
patients24,25. Our results strongly suggest that MCV is not reliable enough to be able to 
exclude causes based on this value alone, when evaluating anaemia in general practice. In 
practice, physicians may start analysis of a potentially anaemic patient by determining the 
haemoglobin and MCV level, and if anaemia is established, they may be led by the MCV 
when deciding on further diagnostic testing. Strictly following MCV-based algorithms may 
result in an incorrect or incomplete diagnosis of the underlying cause or causes of 
anaemia.  
Anaemia type and gender 
ACD and an unknown cause for anaemia were shown to be associated with mild anaemia, 
as has been observed before1,5. For ACD, this association may be explained by the 
underlying disturbance of iron homeostasis in these patients, leading to retention of iron 
within the reticuloendothelial system26. This limits the availability of iron for the 
production of erythrocytes but does not completely abolish their production, resulting in a 
mild anaemia. Since the underlying aetiology of unknown anaemia is unclear, the 
association with mild anaemia is difficult to explain. It is possible  that physicians are more 
reluctant to look for the underlying cause if a patient presents with mild anaemia 
compared to a patient presenting with moderate or severe anaemia. The severe anaemia 
cohort did not show any case of unknown anaemia. General practitioners responded to 
such a low haemoglobin level with a quick, sometimes immediate, referral to the hospital 
where the underlying cause was elucidated and consequently treated. 
By far the most prevalent cause in the severe anaemia cohort was iron deficiency. This 
may be explained by the association of iron deficiency with occult blood loss. This loss 
often happens gradually and goes unnoticed for a long time. This allows the level to 
become severe before a patient visits his or her general practitioner, due to anaemia 
symptoms such as fatigue.  
Shavelle et al (2012)5 described a cohort similar to ours (≥ 50 years, non-institutionalised 
population). However, they only considered the main causes of anaemia. Their study 
showed a comparable prevalence for ACD (26% vs. 29.8%), nutrient deficiency (24% vs. 
23.7%) and renal anaemia (11% vs. 12.3%), but did show a much higher prevalence for 
unknown anaemia (39% vs. 25.4%). This difference may be explained by the inclusion of 
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more possible causes, such as possible bone marrow disease, haemolysis and 
haemoglobinopathy, in our study. The decreased prevalence of unknown anaemia when 
including more possible causes can also be seen in the study by Tettamanti et al (2010)3. 
They analysed a general population aged 65 years and older from Italy and included 
thalassemia as a cause, in addition to the four main causes. Their study found a 
prevalence of 26.4% for unknown anaemia, comparable to the prevalence of 25.4% found 
in our cohort.  
Although a broad range of causes was considered, the proportion of unknown anaemia 
was still high. The difficulty in distinguishing between ACD and IDA, discussed above, may 
partly explain this high proportion. The anaemia was classified as unknown if the ferritin 
level was inconclusive, unless a cause other than ACD or IDA was found. This grey area for 
ferritin in the diagnosis of ACD and IDA is a well-known issue27,28. The most recent DCGP 
guideline, used by GPs in the Netherlands, includes a combined diagnosis of ACD and IDA, 
defined as ferritin in the grey area with lowered serum iron, normal or lowered transferrin 
and microcytic or normocytic anaemia.  The guideline recommends initially treating these 
patients as iron deficient22.    
A possible drawback of this study is the complete reliance on patient records, indicating 
the available clinical data was limited for a considerable number of patients. The 
laboratory tests were not repeated within the study protocol, resulting in cross-sectional 
data collection. However, by determining a broad range of laboratory parameters and 
following strict definitions for the different possible causes of anaemia, this study gives a 
reliable overview of a population of anaemia patients in general practice.  
Conclusion 
This large cohort of patients newly diagnosed with anaemia allowed for a detailed analysis 
of the underlying causes of anaemia in general practice. It was shown that physicians 
should not be solely led by the MCV value in order to exclude causes of anaemia or to 
decide on further diagnostic tests. This study suggests that the existing MCV-based 
algorithms for the evaluation of anaemia should be reconsidered.  
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more possible causes, such as possible bone marrow disease, haemolysis and 
haemoglobinopathy, in our study. The decreased prevalence of unknown anaemia when 
including more possible causes can also be seen in the study by Tettamanti et al (2010)3. 
They analysed a general population aged 65 years and older from Italy and included 
thalassemia as a cause, in addition to the four main causes. Their study found a 
prevalence of 26.4% for unknown anaemia, comparable to the prevalence of 25.4% found 
in our cohort.  
Although a broad range of causes was considered, the proportion of unknown anaemia 
was still high. The difficulty in distinguishing between ACD and IDA, discussed above, may 
partly explain this high proportion. The anaemia was classified as unknown if the ferritin 
level was inconclusive, unless a cause other than ACD or IDA was found. This grey area for 
ferritin in the diagnosis of ACD and IDA is a well-known issue27,28. The most recent DCGP 
guideline, used by GPs in the Netherlands, includes a combined diagnosis of ACD and IDA, 
defined as ferritin in the grey area with lowered serum iron, normal or lowered transferrin 
and microcytic or normocytic anaemia.  The guideline recommends initially treating these 
patients as iron deficient22.    
A possible drawback of this study is the complete reliance on patient records, indicating 
the available clinical data was limited for a considerable number of patients. The 
laboratory tests were not repeated within the study protocol, resulting in cross-sectional 
data collection. However, by determining a broad range of laboratory parameters and 
following strict definitions for the different possible causes of anaemia, this study gives a 
reliable overview of a population of anaemia patients in general practice.  
Conclusion 
This large cohort of patients newly diagnosed with anaemia allowed for a detailed analysis 
of the underlying causes of anaemia in general practice. It was shown that physicians 
should not be solely led by the MCV value in order to exclude causes of anaemia or to 
decide on further diagnostic tests. This study suggests that the existing MCV-based 
algorithms for the evaluation of anaemia should be reconsidered.  
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Supplemental data 
Cause Anaemia (all classes) Men Women 
N % N % N % 
Anaemia of chronic disease 823 29.8 491 36.3 332 23.5 
Haemoglobinopathy 17 0.6 5 0.4 12 0.8 
Haemolysis 16 0.6 5 0.4 11 0.8 
Possible bone marrow disease 105 3.8 54 4.0 51 3.6 
Iron deficiency 516 18.7 196 14.5 320 22.7 
Vitamin B12 deficiency 115 4.2 58 4.3 57 4.0 
Folic acid deficiency 23 0.8 12 0.9 11 0.8 
Renal anaemia 340 12.3 139 10.3 201 14.2 
Other 106 3.8 55 4.1 51 3.6 
Unknown 703 25.4 337 24.9 366 25.9 
Total 2764 100 1352 100 1412 100 
Table 1, Distribution causes of anaemia over gender.  
Cause Anaemia (all age 
groups) 
50-64 65-74 75-84 85+ 
N % N % N % N % N % 
Anaemia of chronic disease 823 29.8 191 27.3 227 36.4 248 29.5 157 26.2 
Haemoglobinopathy 17 0.6 12 1.7 3 0.5 2 0.2 0 0.0 
Haemolysis 16 0.6 4 0.6 2 0.3 8 1.0 2 0.3 
Possible bone marrow 
disease 
105 3.8 30 4.3 23 3.7 35 4.2 17 2.8 
Iron deficiency 516 18.7 199 28.4 106 17.0 128 15.2 83 13.9 
Vitamin B12 deficiency 115 4.2 19 2.7 22 3.5 48 5.7 26 4.3 
Folic acid deficiency 23 0.8 8 1.1 4 0.6 3 0.4 8 1.3 
Renal anaemia 340 12.3 17 2.4 45 7.2 132 15.7 146 24.4 
Other 106 3.8 38 5.4 17 2.7 27 3.2 24 4.0 
Unknown 703 25.4 182 26.0 175 28.0 210 25.0 136 22.7 
Total 2764 100 700 100 624 100 841 100 599 100 
Table 2, Distribution causes of anaemia over the different age groups 
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Cause Anaemia (all types) Mild anaemia Moderate anaemia Severe anaemia 
N % N % N % N % 
Anaemia of chronic disease 823 29.8 765 31.8 51 20.7 7 6.3 
Haemoglobinopathy 17 0.6 16 0.7 0 0.0 1 0.9 
Haemolysis 16 0.6 8 0.3 5 2.0 3 2.7 
Possible bone marrow disease 105 3.8 80 3.3 14 5.7 11 9.9 
Iron deficiency 516 18.7 351 14.6 97 39.4 68 61.3 
Vitamin B12 deficiency 115 4.2 96 4.0 14 5.7 5 4.5 
Folic acid deficiency 23 0.8 16 0.7 6 2.4 1 0.9 
Renal anaemia 340 12.3 299 12.4 32 13.0 9 8.1 
Other 106 3.8 89 3.7 11 4.5 6 5.4 
Unknown 703 25.4 687 28.5 16 6.5 0 0.0 
Total 2764 100 2407 100 246 100 111 100 
Table 3, Distribution causes over the different types of anaemia. 
Cause Anaemia (all 
classes) 
Microcytic 
anaemia 
Normocytic 
anaemia 
Macrocytic 
anaemia 
N % N % N % N % 
Anaemia of chronic 
disease 
823 29.8 26 8.9 763 33.0 34 20.9 
Haemoglobinopathy 17 0.6 16 5.5 1 0.0 0 0.0 
Haemolysis 16 0.6 1 0.3 9 0.4 6 3.7 
Possible bone marrow 
disease 
105 3.8 9 3.1 79 3.4 17 10.4 
Iron deficiency 516 18.7 192 66.0 321 13.9 3 1.8 
Vitamin B12 deficiency 115 4.2 11 3.8 78 3.4 26 16.0 
Folic acid deficiency 23 0.8 3 1.0 12 0.5 8 4.9 
Renal anaemia 340 12.3 14 4.8 303 13.1 23 14.1 
Other 106 3.8 5 1.7 73 3.2 28 17.2 
Unknown 703 25.4 14 4.8 671 29.0 18 11.0 
Total 2764 100 291 100 2310 100 163 100 
Table 4, Distribution causes over the different classes of anaemia 
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Abstract 
Anaemia is a common finding in general practice and is associated with an increased 
mortality. The individual influence of four main causes of anaemia on mortality risk has 
been assessed but information on the potential influence of less prevalent causes is 
lacking. 
We analysed a cohort of community-dwelling patients (≥ 50 years) who presented with a 
newly diagnosed anaemia to their general practitioner. Anaemia was defined as a 
haemoglobin level below 13.7 g/dL (8.5 mmol/L, men) and below 12.1 g/dL (7.5 mmol/L, 
women).  
The total number of included patients was 2929. With this large cohort we confirmed the 
mortality risk associated with anaemia of chronic disease (hazard ratio (HR) = 2.10, 95% CI 
1.64-2.70) and renal anaemia (HR = 2.15, 95% CI 1.61-2.87). In addition to current 
knowledge, possible bone marrow disease (HR = 3.08, 95% CI 1.72-5.52), folic acid 
deficiency (HR = 6.89, 95% CI 2.79-17.04), and multiple causes (HR = 2.31, 95% CI 1.69-
3.16) were shown to be associated with an increased mortality risk, compared to patients 
with an unknown cause of anaemia. Compared to the general Dutch population, an 
increased standardised mortality ratio was observed up to age 85 years. The impact of 
anaemia on mortality risk was particularly severe in the younger age groups. The 
association between mortality risk and anaemia decreased with age.  
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Introduction 
Anaemia is a common condition in a community-dwelling population; the prevalence 
starts rising from the age of 50, from 4.4% in men and 6.8% in women in the age group 50-
64 years, to 26.1% in men and 20.1% in women aged 85 years and older1. Anaemia has 
been associated with frailty, functional decline and decreased quality of life, and is an 
independent predictor of survival1-5. An increased mortality risk associated with anaemia 
was observed among community-dwelling elderly adults6,7, chronic heart failure patients8-
12, haemodialysis patients13,14 and nursing home residents15,16. These studies considered 
the influence of all-cause anaemia.  
Information on how individual causes of anaemia affect mortality is scarce. To the best of 
our knowledge, only two studies have examined the relationship between the aetiology of 
anaemia and mortality, and both were carried out in the United States in a community-
dwelling population. Shavelle et al (2012) used data from the Third National Health and 
Nutrition Survey (NHANES III) to study this relationship in a population aged 50 years and 
older2. The second study, conducted by Semba et al (2007), used information from the 
Women’s Health and Aging Study I, which included moderate to severely disabled women, 
aged 65 years and older, still living at home17. These two studies found a significant 
influence of the aetiology of anaemia on mortality as compared to non-anaemic patients. 
However, only the main causes of anaemia were considered (anaemia of chronic disease 
(ACD), nutrient deficiency anaemia, renal anaemia and unexplained anaemia), which all 
showed a significant impact on mortality risk. There is no information on the influence of 
less prevalent causes of anaemia on mortality.  
The present study analysed the relationship between anaemia aetiology and mortality in a 
population of patients presenting to their general practitioner (GP) with newly diagnosed 
anaemia. Besides the main causes of anaemia, we also took into account less prevalent 
causes such as possible bone marrow disease, haemolysis and haemoglobinopathy. In 
addition, iron deficiency, vitamin B12 deficiency and folic acid deficiency were included as 
separate causes instead of being clustered into nutrient deficiency. The impact of the 
severity of all-cause anaemia on mortality was also determined. To assess the influence of 
all-cause anaemia in this community-dwelling population, standardised mortality ratios 
(SMRs) were determined per five-year age group for each gender.  
Material and methods 
This study was approved by the ethical committee of the Albert Schweitzer Hospital, 
Dordrecht, the Netherlands.  
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Patient inclusion 
The inclusion period lasted from the 1st of February 2007 until the 1st of February 2014. 
The follow-up period ended on the 1st of September 2014. Patients were included after 
presenting to one of the participating general practitioners with a newly diagnosed 
anaemia (i.e. no anaemia in the preceding two years). Both men and women were 
included when aged 50 years or older at the moment of presentation. Anaemia was 
defined as a haemoglobin level below 13.7 g/dL (8.5 mmol/L) for men and below 12.1 g/dL 
(7.5 mmol/L) for women. These haemoglobin levels constitute the cut-off values used by 
general practitioners in the Netherlands as recommended by the Dutch College of General 
Practitioners (DCGP)18. 
Classification causes and types of anaemia 
To determine the cause of anaemia, a standardised laboratory work-up was performed. 
This work-up included haemoglobin, mean corpuscular volume (MCV), erythrocytes, 
erythrocyte sedimentation rate, reticulocytes, thrombocytes, leukocytes, ferritin, 
transferrin, serum iron, serum vitamin B12, serum folic acid, lactate dehydrogenase (LDH), 
creatinine and C-reactive protein (CRP). If, at the discretion of the general practitioner, the 
patient had been referred to the hospital, a hospital chart review was conducted.   
The following causes were included: 1) anaemia of chronic disease (ACD) 2) 
haemoglobinopathy 3) haemolysis 4) possible bone marrow disease 5) vitamin B12 
deficiency 6) iron deficiency anaemia (IDA) 7) folic acid deficiency 8) renal anaemia and 9) 
other. When no cause could be determined, it was classified as unknown. The definitions 
of the included causes are listed in Table 1. The cause of anaemia was established by two 
independent observers (authors KS and ML). In case of a discrepancy, the observers 
deliberated until a consensus was reached. A case classified as renal anaemia could also 
display features of ACD. In these cases, ACD was only classified as a separate cause, if 
there was a clear indication of a concurrent infection or chronic disease. Patients 
presenting with multiple causes were included as a separate group for survival analysis. 
The population was divided into mild (Hb ≥ 10.0 g/dL), moderate (Hb 8.0-9.9 g/dL) and 
severe (Hb < 8.0 g/dL) anaemia in order to assess the influence of the severity of anaemia 
on mortality.  
Survival data 
Patients were followed until either their death or the 1st of September 2014, at which 
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Introduction 
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anaemia. Besides the main causes of anaemia, we also took into account less prevalent 
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Patient inclusion 
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deficiency 6) iron deficiency anaemia (IDA) 7) folic acid deficiency 8) renal anaemia and 9) 
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there was a clear indication of a concurrent infection or chronic disease. Patients 
presenting with multiple causes were included as a separate group for survival analysis. 
The population was divided into mild (Hb ≥ 10.0 g/dL), moderate (Hb 8.0-9.9 g/dL) and 
severe (Hb < 8.0 g/dL) anaemia in order to assess the influence of the severity of anaemia 
on mortality.  
Survival data 
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moment they were censored at the last date they were documented as alive in the 
hospital or laboratory information system. Dates of death were extracted from the same 
systems. 
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Causes Definition 
1) Anaemia of chronic disease Ferritin > 100 μg/L, serum transferrin < 2.0 g/L and/or serum iron < 
14 μmol/L (men), < 10 μmol/L (women) 
2) Haemoglobinopathy Confirmed by DNA testing 
3) Haemolysis LDH > 450 U/L, reticulocytes > 2.5%, bilirubin > 17 μmol/L 
4) Possible bone marrow 
disease 
Abnormal number leukocytes and thrombocytes,  
reticulocytes < 2.5% 
5) Vitamin B12 deficiency Serum vitamin B12 < 130 pmol/L 
6) Iron deficiency Ferritin < 25 μg/L (men), < 20 μg/L (women) 
7) Folic acid deficiency Serum folic acid < 5 nmol/L 
8) Renal anaemia Estimated creatinin clearance (MDRD) ≤ 45 mL/min/1.73 m2  19 
9) Other Reported by treating physician 
10) Unknown No cause could be determined 
Table 1, Definitions of the different causes. The cut-off values were derived from the 
reference intervals used in the Clinical Chemistry laboratory of the Albert Schweitzer 
Hospital where all tests were conducted. 
Data on the mortality of the general Dutch population by age and gender in the year 2010 
was obtained from Statistics Netherlands, which collects and processes national statistics 
in the Netherlands.  
Statistics 
Continuous variables were described using medians and ranges, and categorical variables 
were described using percentages. A Cox proportional hazards model was used to assess 
the influence of anaemia aetiology on mortality. The follow-up time in the Cox model was 
defined as the time from diagnosis of anaemia to the date of death, date of last contact or 
the 1st of September 2014, whichever came first. The independent variables in the model 
were the cause of anaemia, severity of anaemia (mild, moderate or severe), age, and 
gender. Patients with an unknown cause of anaemia were used as reference group in the 
absence of a non-anaemic population. This category was selected as reference since its 
median haemoglobin level was closest to the normal range and due to its size. Mild 
anaemia was designated the reference group for the analysis of the relationship between 
mortality and severity of anaemia. The proportional hazards assumption in this model was 
tested by including interaction effects of the independent variables with time in a Cox 
model with time-dependent covariates. All variables were included in a single 
multivariable Cox model. 
The years at risk were calculated by gender and five-year age groups to determine the 
mortality risk of the anaemic population. This was then compared to the mortality risk of 
the Dutch population in 2010. Confidence intervals of the standardised mortality ratios 
(SMRs) were calculated according to the method Ulm (1990)20. Calculations were 
performed using PASW statistics for Windows, version 18 (SPSS Inc, Chicago, U.S.) and 
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Excel for Windows (Microsoft, Redmond, WA, U.S.). All statistical tests were two-sided and 
used a significance level of 0.05.  
Results 
Causes of anaemia 
A total of 2929 patients were included in the study; 1428 men (median age 72 years, range 
50-101) and 1501 women (median age 77 years, range 50-103). Median follow-up was 29 
months. A single cause could be established in 1843 patients, whereas multiple causes 
(double, triple or quadruple) were established in 260 patients. The cause remained 
unknown in 826 patients. An overview of the prevalence of the different causes of 
anaemia, the median age, and haemoglobin per gender can be found in Table 2.  
The most prevalent causes in the category multiple causes were ACD (114 cases), iron 
deficiency (101 cases), renal anaemia (94 cases) and possible bone marrow disease (77 
cases).  
Survival analysis 
  Causes 
Of the 2929 included patients, 557 (19.0%) died during the follow-up period (Table 2). No 
deaths occurred in the group of patients presenting with haemoglobinopathy and 
therefore no hazard ratio (HR) could be calculated for this cause. The highest proportion 
of deaths occurred in the categories folic acid deficiency (45.5%) and haemolysis (40.0%), 
which showed HRs of 6.89 (95% CI 2.79-17.04, P < 0.001) and 2.64 (95% CI 0.95-7.35, P = 
0.063), respectively. Aside from the category haemoglobinopathy, the lowest proportion 
of deaths was found in patients with unknown anaemia (11.3%, reference group) and iron 
deficiency anaemia (12.4%, HR = 1.15, 95% CI 0.81-1.62, P = 0.435).  
The HRs for the remaining causes in relation to patients diagnosed with unknown anaemia 
were as follows: anaemia of chronic disease (HR = 2.10, 95% CI 1.64-2.70, P < 0.001), 
possible bone marrow disease (HR = 3.08, 95% CI 1.72-5.52, P < 0.001), multiple causes 
(HR = 2.31, 95% CI 1.69-3.16, P < 0.001), renal anaemia (HR = 2.15, 95% CI 1.61-2.87, P < 
0.001), other causes (HR = 1.84, 95% CI 1.01-3.35, P = 0.048), and vitamin B12 deficiency 
(HR = 1.55, 95% CI 0.87-2.77, P = 0.141) (Table 3). No significant violations of the 
proportional hazards assumption were detected.
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Causes Number (%) Median age 
(years) Total Men Women Men Women 
Anaemia of chronic disease 848 (29.0%) 507 (35.5%) 341 (22.7%) 72.0 77.0 
Haemoglobinopathy 18 (0.6%) 5 (0.4%) 13 (0.9%) 56.0 61.0 
Haemolysis 10 (0.3%) 5 (0.4%) 5 (0.3%) 64.0 80.0 
Possible bone marrow 
disease 
42 (1.4%) 25 (1.8%) 17 (1.1%) 66.0 77.0 
Vitamin B12 deficiency 61 (2.1%) 28 (2.0%) 33 (2.2%) 79.5 75.0 
Iron deficiency 499 (17.0%) 182 (12.7%) 317 (21.1%) 66.0 70.0 
Folic acid deficiency 11 (0.4%) 4 (0.3%) 7 (0.5%) 72.0 76.0 
Renal anaemia 290 (9.9%) 120 (8.4%) 170 (11.3%) 82.0 85.0 
Other 64 (2.2%) 37 (2.6%) 27 (1.8%) 63.0 72.0 
Multiple causes 260 (8.9%) 120 (8.4%) 140 (9.3%) 75.0 80.0 
Unknown 826 (28.2%) 395 (27.7%) 431 (28.7%) 72.0 78.0 
Total 2929 
(100.0%) 
1428 
(100.0%) 
1501 
(100.0%) 
72.0 77.0 
Table 2, Overview of the prevalence of each cause and the corresponding median age 
Causes Median haemoglobin (g/dL) # of deaths 
Men Women Total 
Anaemia of chronic disease 12.9 11.4 186 (21.9%) 
Haemoglobinopathy 13.1 11.6 0 (0.0%) 
Haemolysis 11.0 11.1 4 (40.0%) 
Possible bone marrow disease 11.8 10.3 13 (31.0%) 
Vitamin B12 deficiency 13.0 11.4 13 (21.3%) 
Iron deficiency 12.2 10.8 62 (12.4%) 
Folic acid deficiency 10.6 10.2 5 (45.5%) 
Renal anaemia 12.6 11.3 94 (32.4%) 
Other 13.1 11.4 12 (18.8%) 
Multiple causes 12.3 10.6 75 (28.8%) 
Unknown 13.2 11.6 93 (11.3%) 
Total 12.9 11.3 557 (19.0%) 
Table 2 (continued), Overview of the median haemoglobin and number of deaths per 
cause. 
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Severity of anaemia  
A total of 2593 patients (88.5%) presented with mild anaemia, while 229 patients (7.8%) 
and 107 patients (3.7%) were found to have moderate and severe anaemia, respectively. 
The highest proportion of patients who died was found among patients with moderate 
anaemia (24.9%) followed by severe anaemia (22.4%) and mild anaemia (18.4%). A hazard 
ratio of 1.65 was found for both moderate anaemia (95% CI 1.23-2.20, P < 0.001) and 
severe anaemia (95% CI 1.06-2.57, P = 0.028) in relation to mild anaemia (Table 3).  
 Hazard ratio 95% CI P-value 
Cause   < 0.001 
Anaemia of chronic disease 2.10  1.64-2.70 < 0.001 
Haemoglobinopathy 0.00 n/a n/a 
Haemolysis 2.64 0.95-7.35 0.063 
Possible bone marrow disease 3.08 1.72-5.52 < 0.001 
Vitamin B12 deficiency 1.55 0.87-2.77 0.141 
Iron deficiency 1.15 0.81-1.62 0.435 
Folic acid deficiency 6.89 2.79-17.04 < 0.001 
Renal anaemia 2.15 1.61-2.87 < 0.001 
Other 1.84 1.01-3.35 0.048 
Multiple causes 2.31 1.69-3.16 < 0.001 
Unknown Reference 
Type   0.001 
Moderate 1.65 1.23-2.20 < 0.001 
Severe 1.65 1.06-2.57 0.028 
Mild Reference 
Gender    < 0.001 
Female 0.7 0.6-0.8 < 0.001 
Male Reference 
Age 1.07 1.06-1.08 < 0.001 
Table 3, Results from the Cox proportional hazards model.  Since no deaths occurred 
among patients with haemoglobinopathy, 95% CI and P-values could not be calculated for 
this cause. 
Comparison to Dutch population 
The SMR was determined for each five-year age group per gender (Table 4). The age group 
100-104 years was not analysed since data on the Dutch population older than 100 years 
was not available. Statistically significant SMRs higher than one were found for men 
starting in the age group 50-54 years and continuing to the age group 80-84 years. For 
women, significant ratios were established in the age groups 50-54 years, 60-64 years and 
from 70-74 years to 80-84 years. Above age 85 years, no significant impact of all-cause 
anaemia on mortality was observed. 
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Age group Men Women 
Ratio 95% CI Ratio 95% CI 
50-54 years 5.01 1.03-14.64 5.30 1.72-12.37 
55-59 years 4.40 2.01-8.36 2.96 0.81-7.58 
60-64 years 4.32 2.64-6.68 3.57 1.43-7.35 
65-69 years 2.91 1.95-4.17 2.18 0.88-4.50 
70-74 years 1.96 1.30-2.83 2.04 1.09-3.50 
75-79 years 1.69 1.23-2.25 2.09 1.46-2.91 
80-84 years 1.34 1.01-1.73 1.50 1.11-1.99 
85-89 years 1.24 0.94-1.62 1.03 0.79-1.33 
90-94 years 1.15 0.80-1.60 0.97 0.72-1.28 
95-99 years 0.78 0.34-1.54 1.00 0.66-1.45 
Table 4, SMRs by gender and age group. Underlined SMRs are statistically significant. 
Discussion 
Long considered a harmless consequence of ageing, anaemia has been shown to be 
associated with frailty, functional decline, decreased quality of life and an increased 
mortality6,7. However, information on the possible influence of individual causes of 
anaemia on mortality is scarce. To the best of our knowledge, only two studies have 
analysed this potential influence and both only considered the main causes of anaemia; 
ACD, nutrient deficiency, renal anaemia and unknown anaemia2,17. In addition, these 
studies included a relatively small number of anaemic patients, 14717 and 8622, 
respectively, and one study included an all-female population aged 65 years and older17. 
We analysed a large cohort of general practice patients newly diagnosed with anaemia to 
determine the influence on mortality of both the main and less prevalent causes of 
anaemia. In addition, we determined SMRs, by comparing the mortality risks of the 
anaemic cohort and the general Dutch population.  
Five categories of anaemia were shown to be associated with an increased mortality risk, 
namely ACD, possible bone marrow disease, folic acid deficiency, renal anaemia, and 
multiple causes. The considerable proportion of patients (16.4%, data not shown) who had 
already been diagnosed with an underlying malignancy at the moment of presentation or 
were consequently diagnosed,  may account for the increased mortality risk found for the 
category ACD. An earlier study observed a higher prevalence of hypertension, congestive 
heart failure, and diabetes among patients with renal anaemia2; all three underlying 
conditions may explain the increased risk associated with this category. Due to the set-up 
of our study, co-morbidities were not registered and it was therefore not possible to 
corroborate these findings in our own cohort.  
Both Semba et al (2007) and Shavelle et al (2012) had already established an increased 
mortality risk associated with ACD (1.48 and 1.69 respectively) and renal anaemia (1.99 
and 1.70 respectively). These ratios are comparable to the ratios found in our population. 
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The cohort used by Shavelle et al (2012) corresponded closely with ours (community-
dwelling population aged 50 years and older), although their study did control for a 
number of concomitant medical conditions, such as COPD and diabetes. Again, due to the 
set-up of our study, it was not possible to collect such detailed medical information. The 
results obtained from the large cohort of the current study definitely confirm the 
increased mortality risk associated with both ACD and renal anaemia.  
The influence of folic acid deficiency, possible bone marrow disease, and multiple causes 
on mortality risk has not been established before. As in the category ACD, underlying 
malignancies were common among patients with possible bone marrow disease. Half of 
the patients (50.0%) in this category had already been or were consequently diagnosed 
with a malignancy, including diagnoses such as myelodysplastic syndrome (16.7%) and 
acute myeloid leukaemia (11.9%) (data not shown). The category ‘multiple causes’ 
contained a high proportion of ACD, possible bone marrow disease, and renal anaemia, 
which are all causes independently associated with an increased mortality risk. Folic acid 
deficiency was associated with the most severe mortality risk (HR=6.89). This deficiency, 
with or without associated anaemia, is a risk factor for cognitive decline21 and is also 
indicative of a poor nutritional state22,23. Elevated homocysteine levels, which are 
associated with folic acid deficiency, have been connected to an increased risk of major 
medical conditions such as coronary heart disease, stroke, and dementia24,25. Shavelle et al 
(2012) found a hazard ratio of 2.34 for nutritional anaemia (vitamin B12, folic acid or iron 
deficiency). Our data suggest the increased mortality risk associated with nutritional 
anaemia was mostly due to the presence of folic acid deficiency, since independently iron 
deficiency and vitamin B12 deficiency did not significantly affect mortality risk.  
SMRs were determined for each gender per five-year age group to assess the impact of 
all-cause anaemia on mortality in our population of general practice patients. Significantly 
increased SMRs were established up to the age group 80-84 years. The ratios showed a 
decrease with age. Especially in the younger age groups, anaemia had a severe impact on 
mortality risk. In the youngest age group studied, the risk was increased by more than five 
times for both men and women. Anaemia could be relatively easy to treat for these 
patients, and in case the anaemia is due to a severe underlying condition, these patients 
are much more capable of withstanding the treatment necessary for these conditions. The 
proper analysis and treatment of anaemia in these younger age groups may significantly 
improve mortality and possibly also other aspects of life and healthcare on which anaemia 
has an impact.  
Our results show no impact of anaemia on mortality at age 85 years and upwards. This is 
in contrast with results from the Leiden 85-plus study, which found WHO-defined anaemia 
to be associated with an increased mortality risk in a population aged 85 years and 
older26,27. A possible explanation for this discrepancy may be the slightly different 
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Age group Men Women 
Ratio 95% CI Ratio 95% CI 
50-54 years 5.01 1.03-14.64 5.30 1.72-12.37 
55-59 years 4.40 2.01-8.36 2.96 0.81-7.58 
60-64 years 4.32 2.64-6.68 3.57 1.43-7.35 
65-69 years 2.91 1.95-4.17 2.18 0.88-4.50 
70-74 years 1.96 1.30-2.83 2.04 1.09-3.50 
75-79 years 1.69 1.23-2.25 2.09 1.46-2.91 
80-84 years 1.34 1.01-1.73 1.50 1.11-1.99 
85-89 years 1.24 0.94-1.62 1.03 0.79-1.33 
90-94 years 1.15 0.80-1.60 0.97 0.72-1.28 
95-99 years 0.78 0.34-1.54 1.00 0.66-1.45 
Table 4, SMRs by gender and age group. Underlined SMRs are statistically significant. 
Discussion 
Long considered a harmless consequence of ageing, anaemia has been shown to be 
associated with frailty, functional decline, decreased quality of life and an increased 
mortality6,7. However, information on the possible influence of individual causes of 
anaemia on mortality is scarce. To the best of our knowledge, only two studies have 
analysed this potential influence and both only considered the main causes of anaemia; 
ACD, nutrient deficiency, renal anaemia and unknown anaemia2,17. In addition, these 
studies included a relatively small number of anaemic patients, 14717 and 8622, 
respectively, and one study included an all-female population aged 65 years and older17. 
We analysed a large cohort of general practice patients newly diagnosed with anaemia to 
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anaemia. In addition, we determined SMRs, by comparing the mortality risks of the 
anaemic cohort and the general Dutch population.  
Five categories of anaemia were shown to be associated with an increased mortality risk, 
namely ACD, possible bone marrow disease, folic acid deficiency, renal anaemia, and 
multiple causes. The considerable proportion of patients (16.4%, data not shown) who had 
already been diagnosed with an underlying malignancy at the moment of presentation or 
were consequently diagnosed,  may account for the increased mortality risk found for the 
category ACD. An earlier study observed a higher prevalence of hypertension, congestive 
heart failure, and diabetes among patients with renal anaemia2; all three underlying 
conditions may explain the increased risk associated with this category. Due to the set-up 
of our study, co-morbidities were not registered and it was therefore not possible to 
corroborate these findings in our own cohort.  
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mortality risk associated with ACD (1.48 and 1.69 respectively) and renal anaemia (1.99 
and 1.70 respectively). These ratios are comparable to the ratios found in our population. 
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populations. The Leiden 85-plus study included everyone aged 85 years and older in the 
city of Leiden. There was no exclusion based on living situation and patients living in 
nursing homes or long-term care facilities were included. The current study included 
community-dwelling patients visiting their general practitioner due to a specific complaint. 
Since blood tests are usually only ordered when a patient experiences certain complaints 
and consequently visits his or her physician, or if a patient is diagnosed with a condition, 
which requires regular monitoring, our population is more closely based on every day 
practice. The larger size of the current study cohort and its control group may also account 
for the observed discrepancy between studies.  
Due to the effect of anaemia on other aspects of health, such as quality of life, which is an 
important factor in today’s health care, an initial analysis of laboratory parameters is still 
advised in patients aged 85 years and older. A cause such as vitamin B12 deficiency may 
be found with only laboratory analysis and may be easily treated. However, if the initial 
laboratory measurements yield no apparent cause, we recommend to use  any further 
invasive diagnostics with restraint. The risks of these invasive diagnostics may outweigh 
the potential benefits. 
In conclusion, this large cohort of anaemic general practice patients confirmed the 
increased mortality risk associated with the causes ACD and renal anaemia. In addition, an 
increased risk was observed in patients presenting with possible bone marrow disease, 
folic acid deficiency and multiple causes. Especially in the younger age groups anaemia 
was shown to have a severe impact on mortality risk. From age 85 years and older, 
anaemia no longer has a significant impact on mortality and invasive diagnostics to 
determine the cause of anaemia should be used with restraint in this age group.  
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Abstract 
Background: Macrocytic anaemia (MCV ≥ 100 fL) is a relatively common finding in general 
practice. However, literature on the prevalence of the different causes in this population is 
limited. 
Objective: To determine the prevalence of macrocytic anaemia and its aetiology in a 
general practice population and analyse the potential effect of the different causes on 
survival. 
Methods: Over an eight year time period, patients aged 50 years or older and presenting 
to their general practitioner with a newly diagnosed anaemia were included in the study. 
A broad range of laboratory tests was performed for each patient. The cause of anaemia 
was determined by two independent observers based on the laboratory results. 
Results: Of the 3324 included patients, 249 (7.5%) displayed a macrocytic anaemia and 
were subsequently analysed. An underlying explanation could be established in 204 
patients (81.9%) with 27 patients (13.2%) displaying multiple causes. Classic aetiology (i.e. 
alcohol abuse, vitamin B12/folic acid deficiency, haemolysis and possible bone marrow 
disease) was found in 115 patients. Alternative causes (i.e. anaemia of chronic disease, 
iron deficiency, renal anaemia and other causes) were encountered in 101 patients.  
No significant influence of the different causes on survival was observed with multivariate 
analysis.  
Conclusion: In addition to classic explanations for macrocytosis, alternative causes are 
frequently encountered in patients diagnosed with macrocytic anaemia in general 
practice.  
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Background 
Anaemia is regularly encountered in general practice and hospital settings. In a 
community dwelling population, the prevalence of anaemia starts increasing after age 50, 
starting from 4.4% in men and 6.8% in women in the age group 50-64 years and rising to 
26.1% in men and 20.1% in women aged 85 years and older1. Anaemia has been shown to 
be an independent predictor of survival in a population of community-dwelling older 
adults and is capable of negatively influencing quality of life2,3.  
Macrocytic anaemia (MCV ≥ 100 fL) is a relatively common finding. Prevalence estimates 
for macrocytosis range from 1.7% to 3.9%. About 40% of patients presenting with 
macrocytosis display an associated anaemia4,5. Classic causes of macrocytosis include 
nutrient deficiencies (i.e. vitamin B12 and folic acid), alcohol abuse, liver disease, 
haemolysis, medication and primary bone marrow disease (e.g. myelodysplastic syndrome 
(MDS))3-6. Alternative causes include iron deficiency anaemia (IDA), anaemia of chronic 
disease (ACD) and renal anaemia, which are found with moderate or high prevalence in 
anaemia studies. However, the prevalence of these causes in patients with macrocytic 
anaemia remains undetermined.  
A prospective cohort study was set up to systematically evaluate patients presenting with 
anaemia to their general practitioner. Since literature on macrocytic anaemia in general 
practice is limited, this study cohort was used to clarify the prevalence of macrocytic 
anaemia and its aetiology in newly diagnosed anaemia patients in general practice. 
Factors influencing the underlying causes and the potential influence of the different 
causes on survival in a macrocytic anaemia population were also analysed.  
Methods 
Patient inclusion 
This study was approved by the ethical committee of the Albert Schweitzer Hospital. 
Patients were included after presenting to one of the participating general practitioners 
with a newly diagnosed anaemia (i.e. no diagnosed anaemia in the preceding two years) 
between the 1st of February 2007 and the 1st of February 2015. The follow-up period 
ended on the 1st of May 2015. Both men and women aged 50 years or older at the 
moment of presentation were included. Anaemia was defined as haemoglobin level below 
13.7 g/dL (8.5 mmol/L) for men and below 12.1 g/dL (7.5 mmol/L) for women. These 
haemoglobin levels constitute the cut-off values  recommended by the Dutch College of 
General Practitioners (DCGP)7. 
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Cause Definition 
1) Vitamin B12 deficiency Vitamin B12 < 130 pmol/L 
2) Folic acid deficiency Folic acid < 5 nmol/L 
3) Possible bone marrow disease Abnormal number leukocytes and thrombocytes 
Reticulocytes < 2.5% 
4) Haemolysis Raised LDH, reticulocytes > 2.5%, bilirubin > 17 μmol/L 
5) Documented alcohol abuse Reported by treating physician 
6) Anaemia of chronic disease 
(ACD) 
Ferritin > 100 μg/L, serum transferrin < 2.0 g/L and/or serum 
iron < 14 μmol/L (men), < 10 μmol/L (women) 
7) Iron deficiency anaemia (IDA) Ferritin < 25 μg/L (men), < 20 μg/L (women) 
8) Renal anaemia Estimated creatinin clearance (MDRD) ≤ 45 mL/min/1.73 m2  8 
9) Other Reported by treating physician 
Table 1, Definitions of the different causes found in the macrocytic cohort. These cut-off 
values were derived from the reference intervals used in the Clinical Chemistry laboratory 
of the Albert Schweitzer Hospital where all tests were conducted. 
Laboratory work-up 
For each patient, a standardised laboratory work-up was performed, including 
haemoglobin, MCV, erythrocytes, erythrocyte sedimentation rate, reticulocytes, 
thrombocytes, leukocytes, ferritin, transferrin, serum iron, serum vitamin B12, serum folic 
acid, gamma GT, LDH, creatinin and CRP. This work-up allowed for the consideration of a 
broad range of causes of anaemia. At the discretion of the general practitioner, patients 
were referred to the hospital for additional diagnostic testing. For these patients, a 
hospital chart review was conducted and any additional examinations were analysed.  
Classification of causes of macrocytic anaemia 
A classification system was developed, which included the following causes: 1) vitamin 
B12 deficiency 2) folic acid deficiency 3) possible bone marrow disease 4) haemolysis 5) 
documented alcohol abuse 6) anaemia of chronic disease (ACD) 7) iron deficiency anaemia 
(IDA) 8) renal anaemia and 9) other. See Table 1 for the definition of each cause. If no 
cause could be determined, it was classified as unknown.  
Patients diagnosed with renal anaemia also frequently displayed features of ACD. These 
features were considered to be due to the present renal anaemia, and therefore, ACD was 
not classified as a separate cause in these cases. The cause of anaemia was established by 
two independent observers (authors KS and ML). In case of discordance, the observers 
deliberated until a consensus was reached.  
The possible influence of the patient’s age group (50-64 years, 65-74 years, 75-84 years 
and 85+ years) and gender on the diagnosed cause of macrocytic anaemia was also 
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Background 
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Cause Definition 
1) Vitamin B12 deficiency Vitamin B12 < 130 pmol/L 
2) Folic acid deficiency Folic acid < 5 nmol/L 
3) Possible bone marrow disease Abnormal number leukocytes and thrombocytes 
Reticulocytes < 2.5% 
4) Haemolysis Raised LDH, reticulocytes > 2.5%, bilirubin > 17 μmol/L 
5) Documented alcohol abuse Reported by treating physician 
6) Anaemia of chronic disease 
(ACD) 
Ferritin > 100 μg/L, serum transferrin < 2.0 g/L and/or serum 
iron < 14 μmol/L (men), < 10 μmol/L (women) 
7) Iron deficiency anaemia (IDA) Ferritin < 25 μg/L (men), < 20 μg/L (women) 
8) Renal anaemia Estimated creatinin clearance (MDRD) ≤ 45 mL/min/1.73 m2  8 
9) Other Reported by treating physician 
Table 1, Definitions of the different causes found in the macrocytic cohort. These cut-off 
values were derived from the reference intervals used in the Clinical Chemistry laboratory 
of the Albert Schweitzer Hospital where all tests were conducted. 
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documented alcohol abuse 6) anaemia of chronic disease (ACD) 7) iron deficiency anaemia 
(IDA) 8) renal anaemia and 9) other. See Table 1 for the definition of each cause. If no 
cause could be determined, it was classified as unknown.  
Patients diagnosed with renal anaemia also frequently displayed features of ACD. These 
features were considered to be due to the present renal anaemia, and therefore, ACD was 
not classified as a separate cause in these cases. The cause of anaemia was established by 
two independent observers (authors KS and ML). In case of discordance, the observers 
deliberated until a consensus was reached.  
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and 85+ years) and gender on the diagnosed cause of macrocytic anaemia was also 
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analysed. Vitamin B12 deficiency, folic acid deficiency and iron deficiency were combined 
into the cause ‘nutrient deficiency’ for analysis. 
Factors influencing survival 
Survival data was extracted from the hospital and laboratory information systems. 
Patients were followed until either their deaths, or until the 1st of May 2015, at which 
moment they were censored at the last date they were documented as alive in the 
hospital or laboratory information system.  
Patients were classified into six groups for survival analysis; nutrient deficiency (vitamin 
B12 deficiency, folic acid deficiency and iron deficiency), ACD, renal anaemia, multiple 
causes (patients who presented with a double or triple cause, except those presenting 
with only nutrient deficiencies), other (haemolysis, possible bone marrow disease, 
documented alcohol abuse and other) and unknown.  
Statistics 
Continuous variables were described using medians and interquartile ranges (IQR), and 
categorical variables were described using percentages. Fisher’s exact tests were used to 
compare the relative prevalence (among all patients with macrocytic anaemia) of causes 
of anaemia between men and women and between different age groups. These tests 
were performed separately for each cause of anaemia (vitamin B12, folic acid and iron 
deficiency combined into nutrient deficiency) and for each pair of age groups. Kaplan-
Meier analysis and the log rank test were used for an univariate analysis of the association 
between causes of anaemia and survival. A Cox proportional hazards-model correcting for 
the cause of anaemia, age (as a continuous variable), gender, and haemoglobin was used 
for a multivariate analysis of survival. The proportional hazards assumption in this model 
was tested by including interaction effects of the independent variables with time in a Cox 
model with time-dependent covariates. To account for the effects of multiple testing, a 
Bonferroni-adjusted significance level of 0.006 was used for Fisher’s exact tests and a level 
of 0.008 was used for log-rank tests. For all other tests, a two-sided significance level of 
0.05 was used. Calculations were performed using Statistical Package for Social Sciences 
(SPSS) version 18 for Windows. 
Results 
Over the span of eight years, a total of 3324 patients with newly diagnosed anaemia were 
included in the study, of whom 249 (7.5%) patients presented with a macrocytic anaemia; 
140 men (median age 75 years, IQR= 63-82 years) and 109 women (median age 80 years, 
IQR=72.5-87 years). An overview of the patient characteristics can be found in Table 2.  
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A single cause of anaemia was established in 177 patients (71.1%). A double cause was 
established in 26 patients (10.4%) and a triple cause in one patient (0.4%). A total number 
of 232 causes could be established in these 204 patients, while the cause remained 
unknown in 45 patients (18.1%).  
Parameters Median: IQR Reference values  
Age 
- Men 
- Women 
78.0 years: 65.0-85.0 
75.0 years: 63.0-82.0 
80.0 years: 72.5-87.0 
 
Haemoglobin 
- Men  
- Women 
11.8 g/dL: 10.5-12.9 
12.9 g/dL: 11.3-13.2 
11.3 g/dL: 10.2-11.8 
 
13.7-17.7 g/dL 
12.1-16.1 g/dL 
MCV 103 fL: 101-108  
Erythrocytes 
- Men 
- Women 
3.5 10^12/L: 3.0-3.8 
3.8 10^12/L: 3.1-4.0 
3.3 10^12/L: 2.9-3.6 
 
4.6-6.2 10^12/L 
4.2-5.4 10^12/L 
Reticulocytes 1.3%: 0.9-1.8 < 2.5% 
Thrombocytes 218.0 10^9/L: 166.0-272.5 150-400 10^9/L 
Leukocytes 6.7 10^9/L: 5.0-8.7 4.3-10.0 10^9/L 
Ferritin 
- Men 
- Women 
225.0 μg/L: 131.5-464.0 
250.5 μg/L: 137.0-557.8 
197.0 μg/L: 107.0-385.0 
 
25-250 μg/L 
20-150 μg/L 
Creatinin 
- Men 
- Women 
84.0 μmol/L: 70.0-105.5 
88.0 μmol/L: 72.5-105.0 
76.5 μmol/L: 62.0-106.0 
 
59-104 μmol/L 
45-84 μmol/L 
Gamma GT 
- Men 
- Women 
27.5 U/L: 16.0-112.5 
29.5 U/L: 18.0-168.5 
23.0 U/L: 14.0-95.0 
 
< 50 U/L 
< 35 U/L 
Table 2, Patients characteristics of 249 patients with macrocytic anaemia, the interquartile 
range (IQR) is denoted by the first and third quartile. 
Classic causes 
In this cohort, 115 patients (46.2%) presented with a total of 129 classic causes of 
macrocytic anaemia. Vitamin B12 deficiency was found 46 times and folic acid deficiency 
16 times. Documented alcohol abuse was established 31 times, haemolysis 9 times and 
possible bone marrow disease 27 times (Figure 1). Bone marrow examinations performed 
in this last category revealed seven cases of myelodysplastic syndrome (MDS), six cases of 
acute myeloid leukaemia, two cases of chronic lymphoid leukaemia and two cases of 
multiple myeloma. In one patient, no pathology could be found. In six patients with 
possible bone marrow disease, no further examinations were performed due to their 
advanced age. In three patients with possible bone marrow disease, the abnormal  
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analysed. Vitamin B12 deficiency, folic acid deficiency and iron deficiency were combined 
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macrocytic anaemia. Vitamin B12 deficiency was found 46 times and folic acid deficiency 
16 times. Documented alcohol abuse was established 31 times, haemolysis 9 times and 
possible bone marrow disease 27 times (Figure 1). Bone marrow examinations performed 
in this last category revealed seven cases of myelodysplastic syndrome (MDS), six cases of 
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multiple myeloma. In one patient, no pathology could be found. In six patients with 
possible bone marrow disease, no further examinations were performed due to their 
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Figure 1, An overview of the frequency of each established cause in a macrocytic 
population. For each patient the cause or causes were diagnosed by two independent 
observers. 
leukocytes and thrombocytes counts were deemed to be related to the concurrent 
nutrient deficiency.  
Alternative causes 
A total of 103 alternative causes of macrocytic anaemia were found in 101 patients 
(40.6%). IDA was encountered 4 times and ACD was found 55 times. Renal anaemia was 
established 36 times and other causes 8 times (Figure 1). This last category included three 
patients presenting with gastrointestinal bleeding, and three patients diagnosed with 
hypothyroidism. One patient was diagnosed with liver cirrhosis and one patient presented 
shortly after undergoing surgery.  
Unknown cause of anaemia 
Forty-five patients presented with an unknown cause for their anaemia. Two patients 
underwent a bone marrow examination in an attempt to elucidate the underlying cause. 
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One patient was subsequently diagnosed with MDS. For the second patient, the cause of 
anaemia remained unknown.  
Factors influencing diagnosis 
Age  
58, 40, 85 and 66 patients were found in the age groups 50-64 years, 65-74 years, 75-84 
years and 85+ years, respectively. Documented alcohol abuse (Figure 2-A) was most often 
found in the age group 50-64 years (24 of the 31 cases (77.4%)). Significant differences in 
prevalence of this cause were found between age group 50-64 years and the other three 
groups (P < 0.001 for all comparisons). Renal anaemia (Figure 2-B) showed a rising 
prevalence per age group from 1 case in 50-64 years (1.7%) to 19 cases in 85+ years 
(28.8%). For this cause, a significant difference was found between age groups 50-64 years 
and 85+ years (P < 0.001). 
  Gender  
Renal anaemia was diagnosed more often in women compared to men, in 22 of 109 
(20.2%) and 14 of 140 (10.0%) patients, respectively, but this difference was not 
significant (P = 0.019). No other distinct observations were made when analysing the 
influence of gender on the cause of anaemia.  
 
Figure 2, Number of cases per age group for the causes documented alcohol abuse (A) and 
renal anaemia (B) 
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Factors influencing survival 
The median follow-up period lasted 25 months (95% CI 20-28 months). The Kaplan-Meier 
estimate of five-year survival rate from the moment of inclusion was 55.4% (95% CI 46.4-
64.4) for the overall population, with a rate of 57.2% (95% CI 46.0-68.4) for men and a rate 
of 52.5% (95% CI 37.2-67.8) for women. Five-year survival rates were also determined for 
the six groups used for survival analysis: nutrient deficiency (47.9%, 95% CI 27.1-68.7), 
anaemia of chronic disease (56.1%, 95% CI 38.3-73.9), renal anaemia (36.6%, 95% CI 10.1-
63.1), other causes (62.7%, 95% CI 47.0-78.4), multiple causes (58.8%, 95% CI 10.6-107.0) 
and unknown (65.4%, 95% CI 43.4-87.4) (Figure 3).  
The possible influence of the six main causes on survival after entry into the study was 
analysed using a Cox proportional hazards model, correcting for age, gender and 
haemoglobin level. The group ‘unknown’ was selected as reference since the highest five-
year survival rate was observed in this group. However, no significant influence of 
anaemia on survival could be found. No significant violations of the proportional hazards 
assumption were detected.  
 
Figure 3, Kaplan-Meier curves of the survival from the moment of inclusion for the six main 
causes included in survival analysis.  
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Discussion and conclusions 
To determine the prevalence of macrocytic anaemia and its causes in general practice, the 
macrocytic patients of a unique cohort of community-dwelling patients with newly 
diagnosed anaemia were analysed. Both classic and alternative causes of macrocytic 
anaemia were regularly established in this cohort. To the best of our knowledge, this is the 
largest study of macrocytic anaemia patients in general practice to date. Due to the set-up 
of the study, it relied completely on patient records.  
Several algorithms have been developed to aid in diagnosing the underlying cause of 
macrocytic anaemia3,9-11. ACD, IDA and renal anaemia are rarely considered as causes of 
macrocytic anaemia by these algorithms, since these causes are usually reported in 
patients with a microcytic (MCV ≤ 80 fL) or normocytic (80 < MCV > 100) anaemia
10,12,13. 
However, all three causes were frequently encountered in this macrocytic population, 
which has not been demonstrated so clearly in any previous studies.  It is unclear what 
causes this shift towards macrocytosis in these patients. In literature, Andrews (2008) 
mentioned a possible tendency of the erythrocytes in ACD towards macrocytosis, but did 
not explain this further14. Furthermore, patients with IDA, ACD and renal anaemia were, 
on average, only mildly macrocytic compared to patients diagnosed with classical causes 
of macrocytosis, such as nutrient deficiency, alcohol abuse and possible bone marrow 
disease (data not shown).  
For the purpose of this study, a strict limit was used when establishing the presence of 
vitamin B12 or folic acid deficiency. However, values measured just above these limits 
(range 131-200 pmol/L for vitamin B12 and 5-10 nmol/L for folic acid) may not necessarily 
exclude a deficiency. Several patients who were classified as having an ACD, IDA or renal 
anaemia, may have had an additional underlying deficiency of vitamin B12 or folic acid, 
which remained unclassified due to these strict limits. Other possible explanations for the 
presence of ACD, IDA and renal anaemia cases, include an undiscovered underlying 
alcohol abuse or undetected bone marrow disease. Certain medications can also cause 
macrocytosis. However, a complete record of medication was not available for each 
patient.  
According to Younes et al (2013), unexplained macrocytosis may be a prelude to a bone 
marrow disease; 11.6% of their patients developed a bone marrow disease during the 
study period5. However, at the end of the follow-up period of this study, only 1 of the 45 
patients (2.2%) presenting with unknown anaemia was diagnosed with such a disease, 
according to the documentation available in the hospital information system. The strict 
limits used for the classification of vitamin B12 and folic acid deficiency or undetected 
alcohol abuse, as described above, may also explain the presence of macrocytic anaemia 
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in the 44 patients whose cause of anaemia remained unknown (the 45th patient with 
unknown anaemia was subsequently diagnosed with MDS). 
Renal anaemia showed a prevalence rising with age and was found significantly more 
often in patients older than 75 years. This may be explained by the decrease in renal 
function with age15. In addition, renal anaemia was observed more often among women. 
This may be due to the high proportion of women in the two highest age groups; 68.7% of 
the included women were over 75 years old at the time of inclusion versus 45.0% of men.  
Documented alcohol abuse was found most often among those aged 50-64 years. After 
age 65, the prevalence began to decrease. This is consistent with data from a large-scale 
study aimed at determining prevalence of alcohol abuse performed in the United States16.  
The possible influence of different causes of anaemia on survival has not been studied 
before within a macrocytic cohort. However, no significant influence of the causes 
nutrient deficiency, renal anaemia, anaemia of chronic disease, other causes and multiple 
causes on survival was found. The median age of this population was high (78 years), 
which may make age too strong a confounding factor for a survival analysis.   
Macrocytic anaemia was found in 7.5% of patients with a newly diagnosed anaemia in 
general practice. Anaemia of chronic disease, iron deficiency anaemia and renal anaemia 
were frequently encountered as causes in this macrocytic cohort. However, current 
algorithms for the diagnosis of macrocytic anaemia generally do not consider these 
alternative causes. The different underlying causes of macrocytic anaemia could have 
severe consequences should they remain undetected. Thus, a broad diagnostic work-up is 
recommended to completely elucidate the underlying cause of macrocytic anaemia.  
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Abstract 
Introduction: In spite of its relatively high incidence, little is known regarding the diagnosis 
and treatment of anaemia of chronic disease (ACD) in primary care. We set out to study all 
investigations and therapeutic interventions by general practitioners (GPs), and the 
established underlying causes of ACD, to determine the adherence to the national 
guideline in newly diagnosed ACD patients. 
Methods: Information regarding patients with newly diagnosed ACD was obtained from 
the information system of the GP and the referral hospital. ACD is defined as haemoglobin 
below 13.7 g/dL (male) and 12.1 g/dL (female) and ferritin above 100 µg/L combined with 
decreased iron and/or reduced transferrin. 
Results: Of 520 patients with newly diagnosed ACD presenting to 41 participating GPs, 290 
(56%) could be analysed. In 226 of 290 patients (78%), an underlying cause of ACD could 
be established. In 193 patients (67%), additional investigations were required and the 
cause was apparent at the time of diagnosis in 33 patients (11%). The treatments 
administered were in concordance with the national Dutch guideline for 211 patients 
(73%). However, 39 patients (13%) received inappropriate oral iron supplementation. In 
relation to the reference group, survival was poorer in patients with malignancy (P < 
0.001) and tended to be better in patients with autoimmune disease (P = 0.05). 
Conclusions: This unique dataset on the diagnostic and therapeutic strategies of GPs in 
patients with newly diagnosed ACD reveals that the majority of patients were diagnosed 
and treated according to the national guideline, but inappropriate iron supplementation 
was prescribed in a substantial amount of patients.  
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Introduction 
Anaemia is a common finding in general practice and is associated with increased 
mortality, physical and cognitive decline, collapse, fractures, frailty, cardiovascular events 
and reduced quality of life1. One of the most prevalent categories of anaemia is anaemia 
of chronic disease (ACD)2. ACD is caused by a wide variety of conditions, such as acute 
infections, chronic disease (chronic lung disease, diabetes), autoimmune disorders, acute 
trauma, surgical interventions, renal failure, heart failure and malignancies3-7. All of these 
conditions may lead to increased concentrations of inflammatory cytokines, which induce 
the production of the hormone hepcidin. This hormone blocks the release of iron from 
macrophages, hepatocytes and enterocytes by removing the ferroportin receptor from 
the cell membranes of these cells8. In addition, hepcidin causes a down regulation of the 
duodenal absorption of iron. Together, these processes result in a functional iron 
deficiency8. 
The prevalence of ACD has been reported to range from 13.6% to 47.2% in the elderly 
population (≥ 65 years)
2. In a population of patients aged 50 years and older, a relative risk 
for mortality of 1.48 (P < 0.001) was found in patients with ACD compared to adults 
without anaemia9. Due to this impact, it is important that general practitioners (GPs) 
provide the best available care for patients with ACD. In order to do so, the clarification of 
the underlying disease, which is causing ACD, is often necessary. In the Netherlands, the 
Dutch College of General Practitioners (DCGP) provides a guideline for GPs on handling 
newly discovered ACD. This national guideline recommends performing further 
investigations in order to determine the underlying disease, unless a recently incurred 
disease can explain the ACD. Since ACD is associated with a functional iron deficiency and 
oral iron uptake is diminished, the guideline also states that patients with ACD should not 
be treated with oral iron supplementation10. We set out to investigate the diagnostic and 
therapeutic strategies that GPs employ in patients with newly discovered ACD and the 
survival rates of these patients. The adherence of GPs to the national guideline and the 
correlation of different factors, such as gender, age, symptoms, and laboratory results 
with adherence were also investigated.  
Methods 
 Patient inclusion 
From the 1st of February 2007 to the 1st of February 2013 all patients presenting to one of 
41 GPs, who participate in a transmural anaemia intervention programme, with newly 
diagnosed ACD (i.e. no anaemia in the previous two years), were included. This study was 
approved by the internal ethics committee of the Albert Schweitzer Hospital and the 
participating GPs gave permission for the use of anonymous medical information. 
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Anaemia was defined as haemoglobin below 13.7 g/dL (8.5 mmol/L) for males and below 
12.1 g/dL (7.5 mmol/L) for females. ACD was defined as ferritin above 100 µg/L combined 
with decreased serum iron and/or reduced transferrin (i.e. below the lower limit of the 
reference interval)11. Males aged 18 years and older, and females aged 50 years and older 
(in order to exclude a predominance of hypermenorrhea as the cause of anaemia in the 
transmural anaemia project) were included. In order to maintain equality in laboratory 
settings and the criteria to define ACD, all analyses were performed in the clinical 
chemistry laboratory of the Albert Schweitzer Hospital. 
 Data collection 
All investigations, performed from the diagnosis of ACD to either the discovery of the 
underlying cause or the first outpatient visit to the referral hospital, were collected from 
the information systems of both the GPs and the referral hospital. In addition, the time (in 
weeks) from establishing the ACD to diagnosis of the underlying cause, and to death or 
end of follow-up were registered, too. The end of follow-up period was defined as the 
date of data collection from the information system.  
 Typical and atypical presentation 
The symptoms of the patient on the day of blood collections were recorded by the GP. The 
symptoms were classified as atypical or typical complaints. The division was determined 
by experienced internists. Typical complaints consisted of abdominal complaints, rectal 
bleeding, (blood) vomiting, diarrhoea, oedema, renal failure, pain lower 
back/inguinal/lumbago, swollen lymph nodes, vaginal bleeding, heart problems, lung 
problems, haematuria and fever. Atypical complaints consisted of non-localised 
complaints such as tiredness, weight loss, joint pain, malaise, myalgia, itch, 
neck/headache, dizziness, and pain in the extremities. If patients had both atypical and 
typical complaints, the patient was recorded as having typical complaints. 
 Diagnostic and therapeutic strategies 
All investigations ordered by GPs, such as x-ray, endoscopies and ultrasounds, were 
recorded, including those requested in consultation with medical specialists. However, any 
investigations performed after the patient was referred to a medical specialist were not 
included in the analysis. Prescription of oral iron supplementation was registered to help 
determine adherence to the DCGP guideline. Adherence to the DCGP guideline, set as the 
gold standard, was defined as (I) additional investigations in order to clarify the underlying 
illness causing ACD unless an underlying cause was already known, and (II) no oral iron 
supplementation.  
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Underlying causes of ACD 
All underlying causes of ACD were registered, both those diagnosed by the GP and those 
diagnosed by the medical specialist. If the patient was known to also suffer from diabetes, 
chronic lung disease or heart failure, and no other underlying cause of ACD could be 
established, these diseases were assigned as the underlying cause of ACD. 
 Statistical analysis 
The data was analysed using the Statistical Package for the Social Sciences (SPSS) for 
Windows, version 18. The patient population was characterised by standard descriptive 
statistics, such as mean with standard deviation, frequency counts, percentages and 
ranges. Differences in mean haemoglobin levels between two groups were tested using 
the independent t-test. Factors influencing the adherence to the DCGP guideline were 
analysed using binary logistic regression. The survival rates of patients were analysed 
using the Cox regression model. P-values lower than 0.05 were considered significant.  
Results 
 Patient characteristics 
A total of 520 patients presenting with ACD were identified. No records were available for 
230 patients, leaving a total of 290 patients (56%) with a newly discovered ACD for 
analysis. Of these 290 patients, 171 were male (59%) and 119 were female (41%). Patient 
characteristics are shown in Table 1. Symptoms on the day of blood collection were 
registered in 261 patients (90%), and of these patients, 130 (50%) had atypical complains 
and 131 (50%) had typical complaints. In 29 patients (10%) symptoms on day of blood 
collection were unknown or blood was collected as part of a routine examination because 
of another illness. 
Additional investigations by GPs 
In 222 of 290 patients (77%), additional investigations were performed by the GPs after 
ACD was established. In 81 patients (28%), multiple investigations were performed, 
leading to a total of 341 investigations. In 193 patients (67%) the additional investigations 
led to the establishment of an underlying cause of ACD. An overview of all requested 
investigations and the ration to established causes of each investigation is displayed in 
Table 2. Patients who were referred to a medical specialist after establishment of the ACD 
had a mean haemoglobin level of 11.7 g/dL (range 8.1-13.5) as compared to a mean 
haemoglobin level of 12.0 g/dL (range 7.9-13.5) for patients who were not 
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 Mean ± S.D. Reference value 
Age (years): 
- Male 
- Female 
72 ± 13.5 
68 ± 14.7 
77 ± 9.7 
 
Haemoglobin (g/dL): 
- Male  
- Female 
11.9 ± 1.3 
12.5 ± 1.1 
11.0 ± 1.0 
 
13.7-17.7 
12.1-16.1 
Transferrin (g/dL): 1.97 ± 0.36 2.0-3.6 
Ferritin (µg/L): 
- Male 
- Female 
418 ± 352 
446 ± 335 
379 ± 373 
 
25-250 
20-150 
Serum iron (µmol/L): 
- Male 
- Female 
6.6 ± 3.7 
7.1 ± 3.8 
5.9 ± 3.4 
 
14-28 
10-25 
Table 1, Characteristics of ACD patients. S.D.=standard deviation   
 Cause established/frequency (%) 
Physical examination 29/29 (100) 
X-ray 
- Thorax 
- Abdomen 
- Joint 
- Sinus 
 
19/83 (23) 
2/11 (18) 
1/9 (11) 
1/2 (50) 
Ultrasound 
- Abdomen 
- Renal 
 
4/28 (14) 
1/1 (100) 
CT scan 
- Abdomen/thorax 
- Skull 
 
7/13 (54) 
0/1 (0) 
Endoscopy 
- Full endoscopy 
- Gastroscopy 
- Colonoscopy 
 
0/2 (0) 
1/6 (17) 
0/5 (0) 
Referral 
- Internist 
- Emergency room 
- Pulmonologist 
- Geriatrician 
- Rheumatologist 
- Other 
 
61/68 (90) 
29/32 (91) 
13/14 (93) 
8/11 (73) 
9/9 (100) 
8/17 (47) 
Total 193/341 (57) 
Table 2, Ratio of cause established and recorded investigations; values are numbers (%) 
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- Full endoscopy 
- Gastroscopy 
- Colonoscopy 
 
0/2 (0) 
1/6 (17) 
0/5 (0) 
Referral 
- Internist 
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- Other 
 
61/68 (90) 
29/32 (91) 
13/14 (93) 
8/11 (73) 
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8/17 (47) 
Total 193/341 (57) 
Table 2, Ratio of cause established and recorded investigations; values are numbers (%) 
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referred (P = 0.064). An underlying cause of ACD could be determined in 226 of 290 
patients (78%). In 193 patients (67%), the cause was established through additional 
investigations and in 33 patients (11%) the underlying cause was apparent at the time of 
diagnosis of ACD. An overview of all causes is displayed in Table 3.  
Underlying causes of ACD 
In 152 of 193 patients (79%) the time to the diagnosis of the underlying cause could be 
established. The average time was 4.6 weeks (range 0-48). In 50 of 152 patients (33%) the 
underlying cause was established within one week and in 92 of 152 patients (61%) the 
underlying cause could be established within four weeks after presentation (Supplemental 
data 1).  
Malignancy as the underlying cause of ACD was found in 50 patients (22%), of which 25 
were metastatic (50%), 11 non-metastatic (225), eight patients (16%) presented with B-
cell lymphoma and in six patients (12%) no further dissemination investigations were 
performed (type and stage of the malignancies are described in Supplemental data 2).  
 Additional investigations    
(N = 222) 
Underlying disease 
known (N = 33) 
Total 
Underlying cause established 
- Autoimmune disease 
- Infection 
- Renal failure 
- Recent operation 
- Malignancy 
- Diabetes 
- Heart failure 
- Chronic lung disease 
- Other causes * 
193 (87) 
42 (22) 
77 (40) 
4 (2) 
3 (2) 
46 (24) 
7 (4) 
6 (3) 
4 (2) 
4 (2) 
33 (100) 
10 (30) 
0 (0) 
0 (0) 
2 (6) 
4 (12) 
12 (36) 
2 (6) 
1 (3) 
2 (6) 
226 (78) 
52 (23) 
77 (34) 
4 (2) 
5 (2) 
50 (22) 
19 (8) 
8 (4) 
5 (2) 
6 (3) 
No cause established 29 (13) 0 (0) 64 (22) 
Table 3, underlying causes of ACD; values are numbers (%). The percentage of underlying 
causes is calculated from the total amount of causes established in each subgroup. In this 
table, 35 patients, who did not receive additional investigations and in whom no 
underlying cause was established, are not shown. Therefore, the total amount of patients 
with no cause established included 35 more cases. * Other causes such as liver cirrhosis, 
haematoma and alcohol abuse. 
 Survival analysis 
The survival of patients with newly diagnosed ACD for the four main underlying causes 
(autoimmune disease, infection, malignancy or other cause) is shown in Figure 1. In 
addition, the survival of patients, in whom no underlying cause could be established in  
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 Hazard ratio (95% CI) P-value 
Age 1.06 (1.03-1.08) < 0.001 
Gender 1.11 (0.70-1.74) 0.66 
No additional investigations, no cause established Reference  
Autoimmune disease 0.31 (0.09-1.02) 0.05 
Infection 1.15 (0.48-2.74) 0.75 
Malignancy 6.85 (3.11-15.09) < 0.001 
Other causes 1.25 (0.50-3.17) 0.63 
Additional investigations, no cause established 1.35 (0.48-3.78) 0.56 
Table 4, Multivariate analysis of the survival data of ACD patients. The multivariate 
analysis of the survival for the different underlying causes is performed with ‘no additional 
investigations, no cause established’ as the reference group.  
combination with or without additional investigation, is shown. Multivariate analysis 
demonstrated an association between survival and age (HR = 1.06, 95% CI: 1.03-1.08, P < 
0.001). The survival analysis also showed a poor survival rate in patients with malignancy 
(HR = 6.85, 95% CI: 3.11-15.09, P < 0.001) and tended to be better in patients with 
autoimmune disease (HR = 0.31, 95% CI: 0.09-1.02, P = 0.05) in relation to the reference 
group “no additional investigations, no cause established” (Table 4).  
The proportional hazard assumption showed no signification P-values for age (P = 0.79), 
gender (P = 0.71) and underlying cause (P = 0.70) confirming the multivariate analysis 
performed was appropriate for the study population.  
 Odds ratio (95% CI) P-value 
Oral iron supplementation   
Age 0.99 (0.97-1.02) 0.663 
Gender 1.44 (0.64-3.25) 0.375 
Haemoglobin 0.53 (0.32-0.87) 0.012 
Ferritin 0.998 (0.996-1.000) 0.021 
DCGP guideline   
Age 0.99 (0.96-1.01) 0.186 
Gender 1.05 (0.54-2.05) 0.878 
Haemoglobin 0.99 (0.64-1.53) 0.973 
Ferritin 1.00 (1.00-1.00) 0.005 
Transferrin 0.74 (0.33-1.67) 0.468 
Atypical complaints 2.91 )1.22-6.96) 0.016 
Typical complaints 1.81 (0.77-4.27) 0.172 
Table 5, Factors associated with prescription of oral iron supplementation or adherence to 
the DCGP guideline. P-value below 0.05 is considered significant   
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Oral iron supplementation 
Thirty-nine patients (13%) received oral iron supplementation despite being diagnosed 
with ACD and showing ferritin levels above 100 µg/L. Lower haemoglobin and minimally 
raised ferritin levels (above 100 µg/L) are associated with a higher probability of iron 
supplementation, OR = 0.53 (P = 0.012) and OR = 0.998 (P = 0.021), respectively (Table 5). 
GPs adherence to the DCGP guideline 
In 211 of 290 patients (73%) the GP followed the DCGP guideline, consisting of additional 
investigations, unless a recently incurred disease can explain the ACD, in combination with 
no oral iron supplementation. Increased ferritin levels and atypical complaints are 
associated with a higher probability of the DCGP guideline being applied, OR = 1.002 (P = 
0.005) and OR = 2.91 (P = 0.016), respectively (Table 5).  
 
Figure 1, Survival analysis of ACD patients for the diagnostic strategy and underlying cause 
established. The survival of all ACD patients is plotted in different subpopulations. These 
subpopulations consist of the four main underlying causes of ACD, i.e. autoimmune disease 
(blue line), infection (green line), malignancy (black line) or other underlying causes (purple 
line). In addition, ACD patients, in whom no underlying cause could be established, are 
divided in additional investigations (orange line) and no additional investigations (red line). 
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Discussion 
Although many studies have investigated the pathophysiology of ACD and underlying 
causes in hospitalised patients, there is currently little knowledge regarding patients with 
newly diagnosed ACD in primary care. In this study, we described the diagnostic and 
therapeutic strategies of GPs in patients with newly diagnosed ACD and the underlying 
causes of ACD in community-dwelling adults. 
Additional investigations were regularly performed by GPs. In 77% of patients, additional 
investigations were performed, while in 11%, the underlying cause of ACD was already 
known. Only 12% of patients did not undergo additional investigations, which are 
recommended in the national guideline. This may be due to the fact that these patients 
may have been considered too fragile for intensive diagnostics, due to low performance 
status, high age or co-morbidities. Therefore, GPs may consider additional investigations 
in view of a risk-benefit balance12. It is also possible that the underlying cause was not 
documented by the GP. Unfortunately, there was great variation in the completeness of 
the GPs’ notes. GPs rarely record information concerning their instinct, which may affect 
diagnostic strategy.  
If additional investigations were performed, the most common strategy was referral to a 
medical specialist (44%). This may be due to the diagnosis and treatment of the underlying 
cause being outside the scope of the GPs’ focus. The severity of anaemia may be a 
plausible reason in many patients for referral, often leading to blood transfusion. In this 
study, a trend towards a lower haemoglobin was observed in patients referred to a 
medical specialist compared to patients who were not referred (P = 0.064).  
The most common underlying causes of ACD in community-dwelling patients were 
infections (33%), autoimmune inflammation (23%) and malignancies (21%). These 
percentages are in agreement with data acquired in hospitalised ACD patients13,14. 
However, the prevalence of renal insufficiency among hospitalised ACD patients is much 
higher than the prevalence in our study population13,14. Patients who are admitted to 
hospital with severe illnesses have a higher rate of renal insufficiency. Patients with renal 
insufficiency may be more frequently hospitalised or are already being treated by a 
nephrologist, which leads to a lower incidence of renal insufficiency as a cause of newly 
diagnosed ACD in primary care.  
When considering the survival of patients in whom an underlying causes could be 
established, marked differences were seen between the four groups. Those diagnosed 
with a malignancy exhibited the poorest survival. Remarkably, the survival plot did not 
show significant differences between the survival of patients with and without an 
established cause. It is possible that our study population was not large enough to show 
any effect.  
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The diagnostic and therapeutic strategy of GPs was in accordance with the national 
guideline, which recommends additional investigations unless the underlying causes is 
known, in combination with no oral iron supplementation, for 73% of ACD patients. The 
national guideline was more often applied, if patients presented with markedly increased 
ferritin levels. Since increased ferritin in a diagnostic parameter for ACD, noticeable 
elevated levels of ferritin might be an alarm symptom for GPs, which causes them to 
perform additional examinations more frequently. In addition, increased ferritin might 
exclude iron deficiency in the opinion of GPs, preventing the prescription of oral iron 
supplements.  
Patients presenting with atypical complaints were also more often treated according to 
the national guideline. This might be due to the fact that atypical complaints convince GPs 
to order additional investigations or referral instead of the apparent clarity in the cases of 
patients with typical complains, leading to a decision against any investigations or referral.  
Although the adherence to the national guideline is high in this study, it appears that GPs 
prescribe oral iron supplementation in 13% of patients despite ferritin levels above 100 
µg/L. Both lower haemoglobin and moderately raised ferritin levels are associated with an 
increased probability of iron description by the GP. Possibly, GPs are more likely to first 
treat anaemia with oral iron supplementation before determining the underlying causes of 
anaemia. The association of moderately raised ferritin levels and iron supplementation 
might be caused by the absence of a definite ferritin cut-off value defining iron deficiency. 
In conclusion, although inappropriate oral iron supplementation is regularly prescribed, 
we demonstrated a high adherence to the national DCGP guideline. This study provides 
unique information on the diagnostic and therapeutic strategies of GPs’ management of 
patients with newly diagnosed ACD. 
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Supplemental data 
 
Supplemental data 1, Time in weeks until the underlying cause of ACD has been 
established. 
 Established Known Established   
 Metastatic Local Unknown metastatic Total frequency 
Lung 5  2 3 10 
Prostate 2    2 
Mamma 1 1   2 
B-cell lymphoma 4  4  8 
Colon    8 8 
Gastric 2    2 
Oesophagus 2    2 
Elsewhere * 2  4 3 9 
Unknown 6  1  7 
Total 24 1 11 14 50 
Supplemental data 2, Specification of malignancies established as underlying cause of the 
ACD. The primary location and metastatic stage of malignancies are shown. In addition, 
the malignancies are subdivided in either established after the patient was diagnosed with 
ACD or present at time of diagnosing ACD (designated as known). *Elsewhere comprised of 
single malignancies of the brain, larynx, penis, renal, hepatic, melanoma, pancreas, ovary 
and cervix. 
  
Chapter 5 
 
 
92 
Supplemental data 
 
Supplemental data 1, Time in weeks until the underlying cause of ACD has been 
established. 
 Established Known Established   
 Metastatic Local Unknown metastatic Total frequency 
Lung 5  2 3 10 
Prostate 2    2 
Mamma 1 1   2 
B-cell lymphoma 4  4  8 
Colon    8 8 
Gastric 2    2 
Oesophagus 2    2 
Elsewhere * 2  4 3 9 
Unknown 6  1  7 
Total 24 1 11 14 50 
Supplemental data 2, Specification of malignancies established as underlying cause of the 
ACD. The primary location and metastatic stage of malignancies are shown. In addition, 
the malignancies are subdivided in either established after the patient was diagnosed with 
ACD or present at time of diagnosing ACD (designated as known). *Elsewhere comprised of 
single malignancies of the brain, larynx, penis, renal, hepatic, melanoma, pancreas, ovary 
and cervix. 
  
  
  
6 |
The impact of treatment strategy on  
mortality in iron deficiency anaemia
A. Schop
K. Stouten
J. van Rosmalen
J. Droogendijk
R.J. van Houten
J.A. Riedl
M-D. Levin 
Submitted for publication
 The impact of treatment strategy on mortality in iron deficiency anaemia 
 
 
97 
Abstract 
Background: The current recommendations for the treatment of iron deficiency anaemia 
(IDA) in general practice consist of endoscopic evaluation and oral iron supplementation. 
In spite of the high effectiveness of endoscopic evaluation and the high prevalence of 
gastrointestinal malignancies in IDA patients, the rate of endoscopic evaluation by general 
practitioners remains low. 
Methods: IDA was defined as haemoglobin below 13.7 g/dL (male) or 12.1 g/dL (female) 
and ferritin below 25 µg/L (male) or 20 µg/L (female). Information regarding IDA patients 
was obtained from the information systems of the participating GPs and the referral 
hospital. The gold standard for diagnosis and treatment of IDA was defined as a 
colonoscopy performed within four months after the discovery of IDA, combined with oral 
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Introduction 
Anaemia is a common finding in general practice with a prevalence of World Health 
Organisation (WHO)-defined anaemia of more than 10% in adults aged 65 years and 
older1,2. Up to a third of anaemia cases in general practice is related to nutrient deficiency, 
with a large proportion of cases due to iron deficiency anaemia (IDA)3. In the Western 
world, IDA originates mainly from diminished absorption of iron within the 
gastrointestinal tract (GI-tract) or iron loss due to chronic bleeding. The most common 
causes of chronic bleeding are menstrual bleeding, frequent blood donation, 
gastrointestinal blood loss due to polyps, inflammation and malignancies with active 
bleeding4,5. The current recommendations for the treatment of IDA in men and 
postmenopausal women consist of a colonoscopy (preferably in combination with a 
gastroscopy) and oral iron supplementation4-6. 
Previous studies showed that 31 - 47% of IDA patients in general practice receive an 
endoscopic evaluation7-10. In 23 - 86% of these evaluated cases, a lesion potentially 
responsible for GI blood loss is detected and in 2 - 17% of cases this turns out to be a GI 
malignancy7-13. In spite of the effectiveness of endoscopic evaluation and the high 
prevalence of GI-tract malignancies in IDA patients, the rate of endoscopic evaluation by 
general practitioners (GP) remains low in this patient group. This low adherence to 
endoscopic evaluation may have severe consequences for IDA patients. Therefore this 
study investigated the frequency with which the recommended treatment (i.e. a 
colonoscopy in combination with oral iron supplementation) was applied to IDA patients 
in general practice and whether treatment following the current recommendations 
influenced the survival of IDA patients. The factors associated with adherence to the 
recommendations were also investigated.  
Methods 
This study was approved by the ethics committee of the Albert Schweitzer Hospital and 
the participating GPs consented to the use of anonymous medical information. 
Patient inclusion 
From the 1st of February 2007 to the 1st of February 2013, all patients aged 50 years and 
older and presenting to their participating GPs with newly diagnosed IDA (i.e. no anaemia 
in the previous two years) were included in the study. Anaemia was defined as 
haemoglobin below 13.7 g/dL (8.5 mmol/L) for males and below 12.1 g/dL (7.5 mmol/L) 
for females according to the Dutch general practitioners guideline6. Iron deficiency was 
defined as ferritin below 25 μg/l for males and below 20 μg/l for females (i.e. lower limit 
of normal range)14. In order to ensure consistency amongst the laboratory analyses and 
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the criteria used to define IDA, all analyses were performed in the Clinical Chemistry 
laboratory of the Albert Schweitzer Hospital. 
Data collection 
We defined the current recommendations for the treatment of newly discovered IDA in 
general practice as the gold standard, consisting of (I) a colonoscopy (with or without a 
gastroscopy) performed within 4 months after discovery of IDA and (II) oral iron 
supplementation. The four month interval for performing a colonoscopy was based on the 
study of Ioannou et al15. All data was retrospectively collected from the information 
systems of both the GPs and the referral hospital. Colonoscopies requested by GPs and 
prescription of oral iron supplementation were recorded. In addition, predictors of 
survival (i.e. age, gender, and haemoglobin, ferritin and transferrin levels), and date of 
death or end of follow-up were collected. The end of follow-up was defined as the date of 
data collection from the information system or date of death. 
Statistical analysis 
The data was analysed using Statistical Package for Social Sciences (SPSS) for Windows, 
version 18. The patient population was characterized by standard descriptive statistics, 
using frequency counts and percentages for categorical variables, and medians and 
interquartile ranges for continuous variables. The patient population was divided into two 
groups, based on whether the gold standard treatment had or had not been applied. 
Kaplan-Meier curves were used to describe the mortality within each group. Differences 
between groups were analysed with the Fisher’s exact test for categorical variables, the 
log-rank test for mortality, and the Mann-Whitney U test for continuous variables.  
Multivariable logistic regression analysis was used to assess whether age, gender, 
haemoglobin, ferritin, and transferrin were associated with the probability of receiving the 
gold standard treatment. Cox proportional hazards analysis was used to estimate the 
association between receiving treatment according to the gold standard and mortality, 
with adjustment for all the covariates included in the logistic regression analysis. The 
proportional hazards assumption was assessed by testing the interaction effects of the 
covariates with time in a time-dependent Cox proportional hazards analysis. Because the 
proportional hazards assumption was violated for age, we stratified the Cox proportional 
hazards analysis by age categories, using four categories based on the quartiles of the 
observed age distribution. With this approach, the baseline hazard function is allowed to 
differ between age categories. To correct for residual confounding, age was still included  
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 Gold standard 
applied  
Gold standard not 
applied  
Total  
 
P-value 
 (N = 80) 
N (%) 
(N = 162) 
N (%) 
(N = 242) 
N (%) 
 
Gender 
- Male 
- Female 
 
48 (60.0) 
32 (40.0) 
 
46 (28.4) 
116 (71.6) 
 
94 (38.8) 
148 (61.2) 
<0.001a 
Deceased 
- Male 
- Female 
8 (10.0) 
6 (7.5) 
2 (2.5) 
37 (22.8) 
11 (6.8) 
26 (16.0) 
45 (18.6) 
17 (7.0) 
28 (11.6) 
0.018b 
 Median (IQR) Median (IQR) Median (IQR)  
Age (years) 
- Male 
- Female 
64 (58-77) 
64 (58-77) 
64 (54-79) 
66 (52-80) 
66 (61-72) 
64 (52-81) 
66 (54-79) 
66 (59-74) 
64 (52-81) 
0.935c 
Follow-up (months) 34 (21-63) 36 (19-54) 34 (20-56) 0.462c 
Haemoglobin (g/dl) 
- Male (r: 13.7-18.0) 
- Female (r: 12.1-15.1) 
 
11.6 (9.1-13.0) 
9.4 (7.5-11.6) 
 
12.5 (10.8-13.1) 
11.1 (9.7-11.3) 
 
12.2 (9.9-13.0) 
10.9 (9.2-11.6) 
0.264c 
Ferritin (µg/l) 
- Male (r: 25-250) 
- Female (r:20-250) 
 
10 (5-13) 
6 (4-10) 
 
9 (7-13) 
8 (5-12) 
 
10 (6-13) 
8 (4-12) 
0.322c 
 
Transferrin (r: 6.0-8.0 g/dl)  3.6 (3.2-3.8) 3.3 (2.9-3.6) 3.4 (3.1-3.7) 0.002c 
Table 1, Characteristics of IDA patients. The number, percentages, median and 
interquartile ranges of the basic characteristics of both cohorts (i.e. gold standard applied 
or not) and the total population are shown. All laboratory tests were conducted in the 
Clinical Chemistry laboratory of the Albert Schweitzer Hospital. Abbreviations: r = reference 
value. Statistical tests used: a) Fisher’s exact test, b) log rank test and c) Mann-Whitney U 
test. 
 
as a continuous covariate in the Cox proportional hazards analysis. Two-sided P-values 
lower than 0.05 were considered statistically significant. 
 
Results 
Patient characteristics 
A total of 317 patients presenting with IDA were identified. No records were available for 
75 patients, leaving a total of 242 patients (76%) with newly discovered IDA for analysis. A 
total of 80 patients (33%) were treated according to the gold standard, while 162 patients 
(67%) were not. Basic characteristics of both groups can be found in Table 1. 
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Figure 1, Kaplan-Meier of IDA patients stratified by the use of the gold standard. Kaplan-
Meier estimates of the survival of IDA patients in whom the gold standard is applied (green 
line) and in whom the gold standard is not applied (blue line). 
 
 Hazard ratio (95% CI) P-value 
Age (years) 1.10 (1.03-1.17) 0.007 
Gender 2.05 (1.01-4.13) 0.046 
Gold standard 2.63 (1.12-6.18) 0.03 
Haemoglobin (g/dl) 0.90 (0.77-1.04) 0.16 
Ferritin (µg/l) 1.01 (0.95-1.09) 0.72 
Transferrin (g/dl) 0.88 (0.47-1.65) 0.70 
Table 2, multivariate analysis of the survival of IDA patients. Multivariable Cox 
proportional hazards analysis using gender (male versus female), gold standard (not 
applied versus applied) and age, haemoglobin, ferritin and transferrin as continuous 
variables. 
 
Survival analysis 
Of the 80 patients for whom the gold standard was applied, 8 (10%) died during the 
follow-up period. Of the 162 patients, who had not been treated according to the gold 
standard, 37 (23%) died during the study period. The Kaplan-Meier estimates of survival of 
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standard, 37 (23%) died during the study period. The Kaplan-Meier estimates of survival of 
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both groups are shown in Figure 1. The log rank test showed a P-value of 0.018.  
After stratification by age category, the test of the proportional hazard assumption in the 
Cox regression showed non-significant P-values for the interaction of time with age (P = 
0.43), gender (P = 0.58), application of the gold standard (P = 0.50), haemoglobin (P = 
0.24), ferritin (P = 0.23) and transferrin (P = 0.28), thereby confirming the validity of the 
proportional hazard assumption in this model. The Cox proportional hazards analysis 
indicated that male gender was significantly associated with increased mortality risk 
(HR=2.05, 95% CI 1.01-4.13, P = 0.046). In addition, failure to apply the gold standard in 
IDA patients was associated with increased mortality (HR = 2.63, 95% CI 1.12-6.18, P = 
0.03).The hazard ratios for all covariates can be found in Table 2.  
 
 Male N (%) Female N (%) Total N (%) 
Colonoscopy 9 (10) 12 (8) 21 (9) 
Iron supplementation 23 (24) 87 (59) 110 (45) 
Gold standard (i.e. colonoscopy and iron 
supplementation) 
48 (51) 32 (22) 80 (33) 
No colonoscopy and no iron supplementation 14 (15) 17 (11) 31 (13) 
Total 94 (39) 148 (61) 242 (100) 
Table 3, Treatment strategy of general practitioners. Number of requested colonoscopies 
and iron supplementation are shown for male and female IDA patients separately. In 
addition, the number of times the gold standard (i.e. colonoscopy in combination with iron 
supplementation) was applied by GPs is shown.  
 
 Odds ratio (95% CI) P-value 
Age (years) 0.99 (0.96-1.01) 0.30 
Gender (male) 5.53 (2.91-10.51) <0.001 
Haemoglobin (g/dl) 0.79 (0.66-0.95) 0.01 
Ferritin (µg/l) 1.02 (0.95-1.09) 0.68 
Transferrin (g/dl) 2.33 (1.18-4.62) 0.02 
Table 4, Factors associated with adherence to the gold standard. Multivariable logistic 
regression analysis using gender (male versus female) as categorical variable and age, 
haemoglobin, ferritin and transferrin as continuous variables.  
 
Adherence to the gold standard 
In 101 of 242 patients (42%), a colonoscopy was requested by the GP after IDA was 
established. In addition, 190 patients (77%) received oral iron supplementation (Table 3). 
Male gender (OR = 5.53 (P < 0.001)) and increased transferrin levels (OR = 2.33 (P = 0.02)) 
were associated with a higher probability of the application of the gold standard (Table 4). 
In addition, the gold standard was less often applied in patients with less decreased 
haemoglobin levels (OR = 0.79 per mmol/L increase in haemoglobin level (95% CI 0.66-
0.95)). 
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Discussion 
Summary 
For IDA patients in general practice, the gold standard of treatment has been defined as a 
colonoscopy combined with oral iron supplementation. Non-adherence to this gold 
standard was associated with an increased mortality risk in this study, as were age and 
male gender. Furthermore, the gold standard was applied in only 33% of IDA patients, 
mainly due to a low rate of colonoscopies. This study also showed that the gold standard 
was more often applied in males and patients with increased transferrin levels and less 
often applied in patients with less decreased haemoglobin levels.   
Strengths and limitations 
To the best of the authors’ knowledge, this is the first study describing the effect of the 
treatment strategy of IDA patients on mortality in general practice. A possible limitation of 
this study setting is the great variation in the completeness of the GPs’ notes. GPs rarely 
record information concerning their instinct and thought processes, which may affect the 
diagnostic strategy. They may be greatly influenced by the patients’ age, co-morbidities or 
wishes regarding invasive diagnostics and treatment, factors that generally remained 
unrecorded.  
Due to the retrospective design and incomplete notes of GPs, the survival analysis could 
not be corrected for any possible co-morbidities of the IDA patients. In spite of this 
limitation, we were able to correct our model for several other important factors, such as 
age and laboratory parameters detailing iron status, and still found a strong association 
between an increased mortality risk and non-adherence to the gold standard. Despite the 
drawbacks of our study, it was shown that treatment strategy can significantly influence 
mortality. Further research on the relationship between treatment strategy and mortality 
should be undertaken to further elucidate this association.  
Comparison with existing literature 
This study demonstrated that IDA patients who were not treated according to the gold 
standard have an increased mortality risk, as compared to patients to whom this standard 
was applied. There are two possible explanations for this association. First, the GP takes 
not only the laboratory measurements into consideration, but also the patient’s overall 
health, age and wishes regarding invasive diagnostics. In this way, GPs may filter out those 
patients for whom the potential benefits of the invasive procedure of a colonoscopy and 
subsequent interventions no longer outweigh the risks. Especially in elderly patients, 
severe comorbidities and poor overall health status may prevent them from having a 
colonoscopy10. These ‘high risk’ patients may have caused the increased mortality risk in 
the untreated IDA patient. Although we were able to correct for age in the survival 
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Strengths and limitations 
To the best of the authors’ knowledge, this is the first study describing the effect of the 
treatment strategy of IDA patients on mortality in general practice. A possible limitation of 
this study setting is the great variation in the completeness of the GPs’ notes. GPs rarely 
record information concerning their instinct and thought processes, which may affect the 
diagnostic strategy. They may be greatly influenced by the patients’ age, co-morbidities or 
wishes regarding invasive diagnostics and treatment, factors that generally remained 
unrecorded.  
Due to the retrospective design and incomplete notes of GPs, the survival analysis could 
not be corrected for any possible co-morbidities of the IDA patients. In spite of this 
limitation, we were able to correct our model for several other important factors, such as 
age and laboratory parameters detailing iron status, and still found a strong association 
between an increased mortality risk and non-adherence to the gold standard. Despite the 
drawbacks of our study, it was shown that treatment strategy can significantly influence 
mortality. Further research on the relationship between treatment strategy and mortality 
should be undertaken to further elucidate this association.  
Comparison with existing literature 
This study demonstrated that IDA patients who were not treated according to the gold 
standard have an increased mortality risk, as compared to patients to whom this standard 
was applied. There are two possible explanations for this association. First, the GP takes 
not only the laboratory measurements into consideration, but also the patient’s overall 
health, age and wishes regarding invasive diagnostics. In this way, GPs may filter out those 
patients for whom the potential benefits of the invasive procedure of a colonoscopy and 
subsequent interventions no longer outweigh the risks. Especially in elderly patients, 
severe comorbidities and poor overall health status may prevent them from having a 
colonoscopy10. These ‘high risk’ patients may have caused the increased mortality risk in 
the untreated IDA patient. Although we were able to correct for age in the survival 
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analysis, we were unable to correct for comorbidities and health status of the patients. 
Secondly, adherence to the gold standard may aid the early discovery of a GI-tract 
malignancy16,17. This early discovery may lead to an improved cancer-related prognosis 
and thus to a decreased mortality for IDA patients who are treated according to the gold 
standard. 
In addition, the survival analysis in this study demonstrated lower survival rate in male 
patients, which may be explained by a higher incidence of colon carcinoma in males or by 
the lower overall survival rate of men in the Netherlands18,19. Females are often found to 
have a benign underlying cause of IDA (i.e. hypermenorrhoea), while males have a priori 
more likely chance for a malignant cause. 
Only 42% of newly discovered IDA patients received a colonoscopy in the present study, 
which is in line with existing literature7-10. The cause for this low percentage of IDA 
patients receiving a colonoscopy is unknown, since GPs rarely document the reason or 
reasons for refraining from performing one. In this study population, females were more 
likely to be excluded from a colonoscopy. No other common characteristic (e.g. advanced 
age) was found.   
In the present study, the gold standard for treatment of IDA patients was more often 
applied to males. This effect has been observed before7. This may be due to the higher 
incidence of colon carcinoma in men in the Netherlands, which could alert the GP and lead 
to a higher adherence to the gold standard in case the patient is male18. In addition, the 
inclusion criteria of this study only allowed for females aged 50 years and older in order to 
exclude a predominance of hypermenorrhoea as the cause of IDA. However, this age limit 
does not completely exclude all menstruating females. Therefore, it is possible that fewer 
females were referred for a colonoscopy by GPs since hypermenorrhoea was still present 
and these patients did not require further diagnostics according to the current 
recommendations6. 
Finally, increased transferrin levels were associated with a greater adherence to the gold 
standard, while less decreased haemoglobin levels were associated with a lower 
probability of adherence to the gold standard. It is possible that GPs may consider the 
severity of the anaemia when deciding whether or not to apply the gold standard for 
treatment of IDA patients. Increased transferrin levels are observed more often in patients 
with severe anaemia (data not shown). In addition, a recent study showed that IDA 
patients with GI malignancies have significantly lower haemoglobin levels than IDA 
patients without GI malignancies7. These factors may also cause the GPs to adhere more 
strictly to the gold standard. 
Implications for research and/or practice 
The lack of adherence to the gold standard in treatment of IDA patients was found to be 
associated with an increased mortality risk in general practice. This may be due to the 
The impact of treatment strategy on mortality in iron deficiency anaemia 
 
 
105 
detrimental effects of a late diagnosis of colon carcinoma or due to existing comorbidities. 
Although we were able to correct our analysis for age, further research is necessary to 
investigate the influence of other predictors, such as co-morbidities and overall health 
status, on the survival of IDA patients. 
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Abstract 
Differential counting of peripheral blood cells is an important diagnostic tool. However, 
manual morphological analysis using the microscope is time-consuming and requires 
highly trained personnel. The digital microscope is capable of performing an automated 
peripheral blood cell differential, which is as reliable as manual classification by 
experienced laboratory technicians. To date, information concerning the inter-laboratory 
variation and quality of cell classification by independently operated digital microscopy 
systems is limited. We compared four independently operated digital microscope systems 
for their ability in classifying the five main peripheral blood cell classes and detection of 
blast cells in 200 randomly selected samples. Set against the averaged results, the R2 
values for neutrophils ranged between 0.90 and 0.96, for lymphocytes between 0.83 and 
0.94, for monocytes between 0.77 and 0.82, for eosinophils between 0.70 and 0.78, and 
for blast cells between 0.94 and 0.99. The R2 values for the basophils were between 0.28 
and 0.34. This study shows that independently operated digital microscope systems yield 
reproducible pre-classification results when determining the percentages of neutrophils, 
eosinophils, lymphocytes, monocytes, and blast cells in a peripheral blood smear. 
Detection of basophils was hampered by the low incidence of this cell class in the samples.  
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Introduction 
Morphological analysis of blood cells is invaluable to patient management by the clinician. 
Until now, manual morphological assessment using the microscope has been set as the 
gold standard. However, manual assessment of a blood smear is subject to individual 
interpretation of images, resulting in significant inter-observer variability1-3. In addition, 
correct morphological classification is labour-intensive and requires continuous training of 
laboratory personnel. Automated digital morphological assessment of blood cells is 
therefore considered a valuable development, as it can overcome these drawbacks. The 
digital microscope (DM) offers several advantages. First, the DM ensures the constant 
presence of a morphological expert system in the routine laboratory. Second, the system 
stores an image of every analysed cell, thereby offering the ability to re-evaluate cell types 
with colleagues and other pathology experts, either directly or by using tele-
haematology3-6. Finally, the system enables us to digitally archive blood smears and body 
fluid samples indefinitely.  
Since the 1970s, several automated image processing devices have been developed by 
various manufacturers7. It was previously shown that a DM system, using several 
advanced mathematical algorithms, is capable of correct classification of leukocytes in 
peripheral blood and body fluid samples in relation to manual microscopic assessment of 
the five main peripheral blood cell categories3-5,8-10. An overall accuracy of 92.0% was 
found when the pre-classification results of the DM96 (Cellavision, Lund, Sweden) were 
compared to those of manual assessment3,11. It has been shown that the classification 
performance of this particular system is as reliable as manual classification by experienced 
laboratory technicians in classifying the five main peripheral blood cell categories3. 
Only limited information is currently available regarding inter-laboratory variation and 
quality in cell classification by independently operated digital microscope systems. As part 
of the continuing validation of DM systems, it is important to assess the inter-laboratory 
variation between systems operated at different locations and determine whether they 
can produce comparable results. To achieve this, we compared four independently 
operated DM systems when analysing randomly selected samples.  
Materials and methods 
Digital microscope systems and locations 
In this study we set out to compare four independently operated digital microscope 
systems (DM96) for their ability to classify the five main peripheral blood cell classes 
(neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and blast cells in 200 
samples. The DM machines were located at four different clinical chemistry laboratories in 
the Netherlands: the Albert Schweitzer Hospital (ASz), the Vlietland Hospital (Vlietland), 
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the Erasmus Medical Centre, central location (Centrum), and the Erasmus Medical Centre 
Daniel den Hoed Cancer Clinic (Daniel). 
Blood sample collection and analysis 
Using standardised protocols, each laboratory collected peripheral blood samples from 50 
randomly selected patients and generated four blood smear specimens per sample. Each 
hospital location received one smear specimen from each patient. A total of 200 
specimens were analysed at each location. Prior to sample analysis, all four DM systems 
were calibrated using a calibration slide. In addition, each system was set to analyse and 
classify 200 leukocytes per sample. At each location the samples were processed on the 
DM by two local technicians following standardised procedures. This study focused on the 
pre-classification results obtained from the four different DM systems. Pre-classification is 
defined as the initial classification performed by the DM, without intervention or 
correction by the local operator. Therefore, results could not be influenced by manual 
interference.  
Inter-laboratory variation 
The number of each cell type found (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils, and blast cells) was expressed as a percentage of the total amount of cells 
classified. For each location, the individual pre-classification result per cell class was 
compared to the averaged percentage of the other three locations in order to determine 
the inter-laboratory variation.  
Statistics 
The coefficient of determination (R2) was calculated for each comparison in order to 
determine the inter-laboratory variation, using Statistical Package for the Social Sciences 
(SPSS) version 18 for Windows. 
Results and Discussion 
The total number of classified leukocytes did not reach 200 cells in all samples. The range 
in numbers and percentages per cell class per location is shown in Table 1. Figure 1-A-F 
shows scatter plots and the associated R2 value for each comparison per cell class. Overall, 
small inter-laboratory variation was found for neutrophils (R2 = 0.90-0.96), lymphocytes 
(R2 = 0.83-0.94), monocytes (R2 = 0.77-0.82), eosinophils (R2 = 0.70-0.78), and blast cells 
(R2 = 0.94-0.99). Only basophils showed a large variation (R2 = 0.28-0.34). 
 
 
Chapter 7 
 
 
114 
Introduction 
Morphological analysis of blood cells is invaluable to patient management by the clinician. 
Until now, manual morphological assessment using the microscope has been set as the 
gold standard. However, manual assessment of a blood smear is subject to individual 
interpretation of images, resulting in significant inter-observer variability1-3. In addition, 
correct morphological classification is labour-intensive and requires continuous training of 
laboratory personnel. Automated digital morphological assessment of blood cells is 
therefore considered a valuable development, as it can overcome these drawbacks. The 
digital microscope (DM) offers several advantages. First, the DM ensures the constant 
presence of a morphological expert system in the routine laboratory. Second, the system 
stores an image of every analysed cell, thereby offering the ability to re-evaluate cell types 
with colleagues and other pathology experts, either directly or by using tele-
haematology3-6. Finally, the system enables us to digitally archive blood smears and body 
fluid samples indefinitely.  
Since the 1970s, several automated image processing devices have been developed by 
various manufacturers7. It was previously shown that a DM system, using several 
advanced mathematical algorithms, is capable of correct classification of leukocytes in 
peripheral blood and body fluid samples in relation to manual microscopic assessment of 
the five main peripheral blood cell categories3-5,8-10. An overall accuracy of 92.0% was 
found when the pre-classification results of the DM96 (Cellavision, Lund, Sweden) were 
compared to those of manual assessment3,11. It has been shown that the classification 
performance of this particular system is as reliable as manual classification by experienced 
laboratory technicians in classifying the five main peripheral blood cell categories3. 
Only limited information is currently available regarding inter-laboratory variation and 
quality in cell classification by independently operated digital microscope systems. As part 
of the continuing validation of DM systems, it is important to assess the inter-laboratory 
variation between systems operated at different locations and determine whether they 
can produce comparable results. To achieve this, we compared four independently 
operated DM systems when analysing randomly selected samples.  
Materials and methods 
Digital microscope systems and locations 
In this study we set out to compare four independently operated digital microscope 
systems (DM96) for their ability to classify the five main peripheral blood cell classes 
(neutrophils, lymphocytes, monocytes, eosinophils, and basophils) and blast cells in 200 
samples. The DM machines were located at four different clinical chemistry laboratories in 
the Netherlands: the Albert Schweitzer Hospital (ASz), the Vlietland Hospital (Vlietland), 
Digital microscopy and inter-laboratory reproducibility 
 
 
115 
the Erasmus Medical Centre, central location (Centrum), and the Erasmus Medical Centre 
Daniel den Hoed Cancer Clinic (Daniel). 
Blood sample collection and analysis 
Using standardised protocols, each laboratory collected peripheral blood samples from 50 
randomly selected patients and generated four blood smear specimens per sample. Each 
hospital location received one smear specimen from each patient. A total of 200 
specimens were analysed at each location. Prior to sample analysis, all four DM systems 
were calibrated using a calibration slide. In addition, each system was set to analyse and 
classify 200 leukocytes per sample. At each location the samples were processed on the 
DM by two local technicians following standardised procedures. This study focused on the 
pre-classification results obtained from the four different DM systems. Pre-classification is 
defined as the initial classification performed by the DM, without intervention or 
correction by the local operator. Therefore, results could not be influenced by manual 
interference.  
Inter-laboratory variation 
The number of each cell type found (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils, and blast cells) was expressed as a percentage of the total amount of cells 
classified. For each location, the individual pre-classification result per cell class was 
compared to the averaged percentage of the other three locations in order to determine 
the inter-laboratory variation.  
Statistics 
The coefficient of determination (R2) was calculated for each comparison in order to 
determine the inter-laboratory variation, using Statistical Package for the Social Sciences 
(SPSS) version 18 for Windows. 
Results and Discussion 
The total number of classified leukocytes did not reach 200 cells in all samples. The range 
in numbers and percentages per cell class per location is shown in Table 1. Figure 1-A-F 
shows scatter plots and the associated R2 value for each comparison per cell class. Overall, 
small inter-laboratory variation was found for neutrophils (R2 = 0.90-0.96), lymphocytes 
(R2 = 0.83-0.94), monocytes (R2 = 0.77-0.82), eosinophils (R2 = 0.70-0.78), and blast cells 
(R2 = 0.94-0.99). Only basophils showed a large variation (R2 = 0.28-0.34). 
 
 
Chapter 7 
 
 
116 
Table 1, Ranges for each cell class found at the different locations (ASz, Centrum, Daniel, 
and Vlietland) 
As part of the continuing validation of DM systems for morphological analysis of a 
peripheral blood smear, the inter-laboratory variation for the five main blood cell classes 
and blast cells was determined. This is the first published study that considers this 
variation between independently operated digital microscopy systems. The pre-
classification results show small inter-laboratory variation for four of the five main 
peripheral blood cell classes. This is comparable to R2 values found when comparing two 
manual differential counts, as done by Ceelie et al3. The DM showed even less variation 
between several machines than between the two manual differentials for neutrophils (R2 
= 0.90 for manual count) and monocytes (R2 = 0.65 for manual count)3. 
Blast cells were detected with an excellent accuracy, despite the fact that the overall 
average percentage of blast cells was low. This is probably due to the large spread in 
counted cells per sample. Not every sample contained blast cells, which lowers the overall 
average percentage. The same was observed when two manual counts of blast cells were 
compared, resulting in an R2 value of 0.973. Again, the DM showed even less variation 
between systems than between experienced morphologists, since R2 values between 0.94 
and 0.99 were found in this study.  
Only the pre-classification results of the basophils showed considerable inter-laboratory 
variation. This variation was also seen when comparing manual assessment by an 
experienced morphologist to a reference differential, as done by Briggs et al4. Even an 
experienced morphologist could not achieve an R2 value higher than 0.30 when manually 
classifying basophils. Briggs et al4 also compared the manual differentials executed by two 
experienced morphologists with the DM. This resulted in an R2 value of 0.004. Similar 
results were found by Ceelie et al3when comparing two manual differential counts with 
each other and with the DM. The poor R2 values for basophils are due to the low number 
of detected cells of this class per peripheral blood smear, leading to profound relative 
differences in detected percentages of basophils at different locations. 
 
 ASz Centrum Daniel Vlietland 
 # % # % # % # % 
Neutrophils 2-189 1.1-96.9 0-192 0.0-97.0 0-191 0.0-97.4 0-190 0.0-96.9 
Lymphocytes 0-184 0.0-92.4 1-179 0.5-92.7 2-187 1.0-93.5 1-178 0.5-90.8 
Monocytes 1-73 0.5-38.2 1-65 0.5-35.7 0-75 0.0-39.3 0-75 0.0-40.8 
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Figure 1 (previous pages), Results of pre-classification comparisons for segmented 
neutrophils (A), lymphocytes (B), monocytes (C), eosinophils (D), basophils (E), and blast 
cells (F). The Y axis shows the percentages of classes found in each of the 200 samples per 
location (ASz, Centrum, Daniel, and Vlietland). The X axis shows the average percentage of 
the different cells classes found at the four locations excluding the location on the Y-axis.  
A database containing approximately 1.4 million leukocytes was set up to compare the 
pre-classification performance of the DM with the manual assessment of peripheral blood 
smears by experienced morphologists. This database yielded an R2 value of 0.88 for the 
basophils (Riedl, data not yet published). The size of that database overcomes the 
problem encountered in this study, which was hampered by the low number of counted 
basophils in the various samples. The same was observed in a study by Lee et al12, who did 
not include normal blood smears and therefore may have had more basophils than is 
usually observed. Their comparison between the DM96 and a manual count gave an R2 
value of 0.7612. 
In conclusion, this study shows that independently operated digital microscope systems, 
stationed at four different locations, yield reproducible pre-classification results when 
determining percentages of neutrophils, lymphocytes, monocytes, and eosinophils 
present in a blood smear. In addition, blast cells were also detected correctly and with 
only minor variation in detected percentages between the different microscopy systems. 
The classification of basophils was less accurate because of the low number of basophils 
present in these samples.  
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The analysis of blood morphology is of great diagnostic importance to the clinician. 
Manual morphological assessment using the microscope has been considered the gold 
standard for years but can be vulnerable to inter-observer variability, is labour intensive, 
and requires highly and continuously trained personnel1-3. An exciting development in the 
field is the introduction of digital microscope (DM) systems. A DM ensures the constant 
presence of a morphological expert in the routine laboratory and enables the automatic 
recognition of (pathological) cell types3-5. 
It was previously shown that the classification performance of the DM is equal to manual 
performance when classifying the five main peripheral blood cell classes (neutrophils, 
lymphocytes, monocytes, eosinophils, and basophils)3-9. However, these studies either 
used a low number of samples and cells or did not include a combination of normal and 
abnormal peripheral blood smears (PBS)3-9. Several studies also compared post-
classification results (which include manual interference) with manual analysis preventing 
a clear view on the ability of the DM to correctly classify cells without manual 
interference4,6,7. Here, we present a large-scale database of about 1.4 million leukocytes 
from both normal and abnormal PBS, pitting the DM’s pre-classification performance 
against the gold standard. 
Methods 
Patient samples 
Venous blood was collected using K3-EDTA as anticoagulant and stored at room 
temperature until further analysis. Within 4 hours of collection, blood smears were 
prepared and stained according to Romanowsky (May-Grunwald/Giemsa/Wright), using 
an automated slide preparation unit (SP-100, Sysmex, Kobe, Japan). The number of cells 
analysed per slide was set at 200, both for manual assessment and assessment by the DM. 
Manual assessment, set as the gold standard, was defined as analysis of a slide by an 
experienced morphology expert by reviewing the digital images provided by the DM. The 
pre-classification performance, defined as the initial classification by the DM without 
manual intervention, was compared to this gold standard. The samples were selected 
from our laboratory which handles routine samples from both general practitioners and 
hospitals, including a haemato-oncology ward.  
Automated microscopy system 
For this study, the DM96 (Cellavision, Lund, Sweden), described in reference 3, was used 
as DM system, operated with the Cellavision Blood differential module (Version 2.0). 
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Statistics 
Statistical analysis was carried out using Statistical Package for Social Sciences (SPSS) 
version 18 and Medcalc version 15, both for Windows. The study design was based on the 
National Committee for Clinical Laboratory Standard document H20A. To determine 
accuracy, the percentage of each class per sample found by the DM was compared to the 
percentage found by the manual assessment. Results were analysed according to Bland 
and Altman10, and by determining the Pearson product-moment correlation coefficient 
(R). To generate Bland-Altman plots, the difference (percentage DM minus percentage 
expert) per sample was shown as a function of the mean result of both DM and expert. 
Mean difference and limits of agreement (mean difference ± 1.96*standard deviation) 
were determined and added to the plots as reference lines. Constant and proportional 
biases were assessed using Deming regression.  
Results 
A total of 6945 PBS were analysed with approximately 1.4 million classified cells. When 
possible, 200 cells per sample were analysed. In 214 cases (3.1%), the DM did not reach 
the number of 200 cells due to leukopenic samples. In 57 cases (0.8%), the number of 
counted cells was below 100 (minimum 16 cells). As the number of cells in each class was 
expressed as a percentage of the total number of counted cells, these samples were 
included in the analysis. 
The results for the different leukocyte classes and nucleated red blood cells (NRBCs) can 
be found in Table 1 and Figure 1. Pre-classification performance has an excellent accuracy 
for the five main blood cell classes and NRBCs. The DM software is currently unable to 
recognise promonocytes, prolymphocytes, hairy cells, and cleaved cells; these were only 
counted by the experts.  
Proportional bias was found to be present for the five main classes and metamyelocytes 
and ranged from 0.5% for neutrophils to 23.3% for metamyelocytes. Constant bias was 
found to be present for nine classes and ranged from 0.04% for basophils to 0.39% for 
blast cells.  
For blast cells, the limit for a positive finding was set at 0 for the DM, defining a 
percentage above 0.0% as positive. With this limit, the DM achieved a blast cell sensitivity 
of 100% with a specificity of 67%.  
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Cell classes Correlation Mean 
difference 
Limits of 
agreement 
Regression 
equation 
95% CI 
intercept 
95% CI slope 
Neutrophils 0.997 -0.147 -3.385-3.091 0.16+0.99x  0.05-0.27*  0.99-0.99* 
Lymphocytes 0.995 -0.461 -4.767-3.845 0.38+0.97x  0.31-0.46*  0.97-0.98* 
Monocytes 0.933 -0.151 -4.140-3.838 0.21+0.95x -0.10-0.51  0.90-0.99* 
Eosinophils 0.978 -0.099 -1.339-1.141 0.09+0.91x  0.07-0.11*  0.90-0.92* 
Basophils 0.928 -0.062 -0.864-0.740 0.04+0.84x  0.01-0.07*  0.80-0.89* 
Blast cells 0.840  0.367 -3.298-4.032 0.39+0.93x  0.36-0.41*  0.79-1.07 
Promyelocytes 0.432  0.027 -1.361-1.415 0.05+0.60x -0.01-0.10 -0.99-2.18 
Myelocytes 0.808  0.139 -1.707-1.985 0.16+0.94x  0.08-0.25*  0.68-1.21 
Metamyelocytes 0.802 -0.021 -2.037-1.995 0.09+0.77x  0.02-0.15*  0.59-0.95* 
Plasma cells 0.576  0.114 -1.121-1.349 0.13+0.67x  0.09-0.16* -0.61-1.94 
NRBCs 0.958  0.333 -1.660-2.326 0.32+1.03x  0.30-0.34*  0.99-1.06 
Table 1, Overview of the correlation, mean difference, limits of agreement, regression 
equation, and the corresponding 95% confidence intervals (CI) for the intercept and the 
slope of the regression equation. The classes promonocytes, prolymphocytes, hairy cells, 
and cleaved cells cannot yet be detected by the DM and were therefore not included in this 
table. Neutrophils include band and segmented neutrophils. Lymphocytes also included 
variant lymphocytes. The mean difference and limits of agreement were added to the 
Bland-Altman plots as reference lines. The regression equation and the corresponding 95% 
confidence intervals were used to assess constant and proportional bias. Significant biases 
are highlighted with an asterisk.  
Discussion 
Before digital microscopy can be accepted as an improvement over the current manual 
method and used as a standardized diagnostic tool, it is necessary to establish that the 
systems are as reliable as manual assessment4. A large database of leukocytes was used to 
compare the pre-classification performance of the DM to morphological experts. 
The detection of blast cells is essential for the correct and early diagnosis of patients with 
haematological malignancies. It is therefore of extreme importance that the DM does not 
miss any blast cells (i.e. displays a high sensitivity). In the current study, the DM achieved a 
blast cell sensitivity of 100% and a specificity of 67%. The rather low specificity indicates 
that, quite often, the DM classifies a leukocyte as a blast cell, while the cell actually 
belongs to a different class. In several cases, the expert found a higher percentage of blast 
cells compared with the DM. While the DM shows excellent sensitivity for blast cells, it 
does remain necessary for the operator to routinely check the exact percentage. 
Excellent accuracy was found for the five main cell classes as shown by the small limits of 
agreement approaching 0, in combination with the high correlation. The mean differences 
shown in the Bland-Altman plots were small enough to be considered clinically 
insignificant10. However, rare individual cases may show large differences between the  
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 Figure 1, Bland-Altman plots for A) neutrophils, B) lymphocytes, C) monocytes, D) 
eosinophils, E) basophils, F) blast cells, G) promyelocytes, H) myelocytes, I) 
metamyelocytes, J) plasma cells, and K) NRBSc. 
results obtained by the DM and by the expert. In these cases, the DM generally classified 
cells into one of the five main classes, while the expert classified the cells into one or 
several of the less common classes. 
A statistically significant proportional bias was present for the five main classes, but was 
too small to be considered clinically relevant, as determined by an experienced 
haematologist. Constant bias was found for nine classes, including four of the five main 
classes, but was small enough to be considered negligible. However, when analysing a 
database of this size, even small biases are statistically significant.  
The DM’s performance for less common cell classes ranged from adequate (blast cells, 
correlation = 0.840) to poor (promyelocytes, correlation = 0.432), with small mean 
differences. However, the majority of samples did not contain these classes according to 
both the DM and the expert. The calculated mean difference was 0 in these cases, 
markedly lowering the mean. For these classes, Bland-Altman plots may not be the most 
fitting method for the analysis of the results. Metamyelocytes showed a clinically 
significant proportional bias. However, the algorithms used by the DM for this class, and 
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for the other less common classes, are still in development. Further work is needed to 
enhance the DM’s performance for these classes. 
Four rare but clinically significant classes – promonocytes, prolymphocytes, hairy cells, and 
cleaved cells – cannot yet be detected by the DM. The operator can use the overview 
option of the DM to review the complete slide after pre-classification to check the DM’s 
performance and detect these rare classes. In practice, the DM can be used as a screening 
tool for peripheral blood smears, saving time, and reducing workload. The presence of the 
operator is still required to ensure the proper classification of the less common and rare 
cell classes. 
The next step in morphology will be automated assessment of blood samples, which will 
allow a blood sample to be processed by a cell counter, an automated preparation unit, 
and a DM system without any manual intervention, while the results obtained can be sent 
to the laboratory information system without manual confirmation. This will decrease 
labour costs (an important issue in today’s healthcare system), minimize inter-observer 
variability, and reduce reporting time for morphological assessment of PBS. The database 
described here will next be used to assess the possibility of autovalidation of a DM system, 
which will, if successful, exclude manual interference. 
In conclusion, the DM is capable of an excellent performance for the five main blood cell 
classes and blast cells, but at this moment, manual intervention remains necessary to 
‘help’ the system with the less common classes and the occasional outlier. The algorithms 
used by the DM to classify the less common classes do require further refinement to 
improve the DM’s pre-classification performance. Nonetheless, the current pre-
classification performance of DM systems is a significant step toward the acceptance of 
DM systems as the standard diagnostic tool for morphological assessment.  
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Anaemia is a significant health problem across the world. It is predominant in the most 
vulnerable population groups; children below five years of age and the elderly (≥ 65 
years)1,2. Anaemic children may have issues with mental and motor development1. In the 
elderly anaemia is associated with detrimental effects on many aspects of health, such as 
an increased risk of recurrent falls3-5 and more frequent hospital admissions6-10, and 
increased mortality rates7-9,11-25. Anaemia is considered a symptom of diverse underlying 
aetiology. The most common causes are anaemia of chronic disease (ACD), iron deficiency 
anaemia (IDA), renal anaemia, and unknown anaemia (Chapter 2 and 3). The less 
prevalent causes, such as haemolysis and possible bone marrow disease, generally get 
little attention in population-based anaemia studies. Knowledge regarding their individual 
impact on survival is lacking as well.  
In this thesis, we focused on patients presenting to their general practitioner (GP) with 
newly diagnosed anaemia. GPs have a central role in the healthcare system, as they 
usually are the first specialist a patient comes in contact with when seeking medical aid. 
As such, GPs encounter a wide variety of patients and conditions, and anaemia is a 
common finding. Clear prevalence rates of a broad range of causes and proper guidelines 
are necessary to aid physicians with the evaluation of anaemia. We analysed several 
causes of anaemia, their individual impact on mortality risk and their prevalence rates in 
an anaemic community-dwelling population (≥ 50 years). We also analysed the predictive 
value of the mean corpuscular volume (MCV) to determine the validity of the current 
MCV-based guidelines for the evaluation of anaemia. 
 Defining anaemia  
Anaemia is most commonly defined by a cut-off value of haemoglobin. Most publications 
use the cut-off values determined by the World Health Organisation (WHO)1. However, 
the WHO standard has become a topic of debate during the past decade since it was 
determined over 45 years ago in a small number of subjects and does not take potential 
differences between races into account. Alternative values, based on a larger population 
database, have been suggested by Beutler et al26, but the WHO standard is still 
maintained. Our research focused on a population of general practice patients in the 
Netherlands. Therefore, we used the cut-off values recommended by the Dutch College 
for General Practitioners (DCGP)27,28 to define anaemia in this thesis. These values are 
used in daily practice in the Netherlands, where all described studies were conducted. Its 
use therefore more accurately reflects day-to-day reality of the patients included in our 
database, compared to the internationally recognised WHO standard. 
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Anaemia diagnostics 
 MCV-based classification of anaemia 
Establishing the presence of anaemia is relatively straightforward but determining the 
underlying cause may be challenging. And yet, elucidating this cause is necessary for the 
swift and correct treatment of both the anaemia and any potential underlying conditions. 
Without a clear aetiology, targeted therapy becomes very difficult29. Several algorithms 
have been developed to aid physicians with the evaluation of anaemia27,30-32. Most of 
these algorithms follow the hallmark classification based on MCV. This classification was 
first postulated by Wintrobe in the 1930s and has remained leading ever since33. Despite 
its extensive use in anaemia evaluation, the actual value of MCV in daily practice has been 
insufficiently studied. Several relatively small studies in elderly hospitalised patients have 
shown that MCV does not have any added value for the evaluation of anaemia in this 
population34-36.  
In Chapter 2 we analysed the validity of MCV-based algorithms in general practice. A 
traditional classification emerged from statistical testing but a strict application of these 
results culminated in almost 30% of causes found in the ‘wrong’ class. The negative 
predictive value of MCV was considered too low for six of the causes to be able to reliably 
exclude them based on MCV alone. This could only be partly explained by the often 
multifactorial nature of anaemia in this population. These findings were supported by the 
results in Chapter 4, where the analysis of the macrocytic cohort of our population 
database showed a considerable prevalence of laboratory findings compatible with 
anaemia of chronic disease (ACD), iron deficiency anaemia (IDA) and renal anaemia. All 
three causes had not been described in a macrocytic cohort before and should not be 
found in this cohort according to the traditional classification. Based on this data we 
concluded that the validity of the use of MCV in the evaluation of anaemia in general 
practice could not be substantiated.  
 Future anaemia algorithms 
In Chapters 2 and 4, we demonstrated that the predictive value of MCV is simply not 
strong enough to justify excluding causes based solely on this parameter. This leads to the 
conclusion that the existing MCV-based algorithms for the evaluation of anaemia should 
be reconsidered. A first step towards developing algorithms without MCV is the new DCGP 
guideline used in the Netherlands. It puts less emphasis on MCV, but its developers did 
not venture to remove the parameter entirely.  
Aside from removing MCV from the criteria, the new generation of algorithms should 
incorporate several aspects. There should be a move towards a digital algorithm, in which 
the results of a standardised laboratory anaemia protocol can be uploaded. The algorithm 
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can then show a probability score for each cause, giving physicians a good overview of the 
contributing factors for the patients’ anaemia. The protocol should at least contain the 
following parameters: haemoglobin, ferritin, iron, transferrin, transferrin saturation, C-
reactive protein, vitamin B12, folic acid, erythrocytes, thrombocytes, leukocytes, 
creatinine/MDRD, and LDH. These parameters are most commonly included in the current 
evaluation of anaemia and laboratories should therefore have no difficulty implementing 
the digital algorithm. This batch of tests also allows for the diagnosis of a wide range of 
causes. More recently developed parameters, such as the soluble transferrin receptor, 
may also be included, if their added worth can be demonstrated. Hepcidin has emerged as 
a marker capable of distinguishing between ACD and IDA when ferritin is inconclusive37,38. 
However, standardisation of the available tests remains an issue and determining the 
parameter is currently still quite costly, and not widely available in laboratories. Hepcidin 
also does not give a decisive test result for patients presenting with both ACD and IDA, 
which remains a difficult combination to diagnose and treat. This prevents hepcidin from 
being an appropriate parameter to include in a diagnostic anaemia algorithm at this point 
in time. 
 Since anaemia is often multifactorial, especially in the elderly population (Chapter 2 and 
3)39, we should move away from the strict ‘one cause only’ precedent set by the current, 
non-digitalised algorithms. A digital algorithm will allow for several possible causes per 
patient and also show corresponding probability scores per cause. To summarise, in the 
future, a physician should be able to upload the results from a standardised laboratory 
protocol into an algorithm and receive an overview of the possible causes and the 
probability of these causes contributing to the present anaemia.   
In future research, the population database described in this thesis will be used to create a 
digitalised, evidence-based algorithm for the evaluation of anaemia. Besides allowing for a 
multifactorial approach, this algorithm could lower the percentage of unexplained cases of 
anaemia in general practice. Decreasing the prevalence of unexplained anaemia will 
facilitate an increase in correctly treated anaemia cases.  
 Other factors 
An earlier review noted that there is no correlation between the severity of anaemia and 
its underlying causes40. This observation is in contrast with our findings in Chapter 2. Our 
data does suggest there is an association between the cause and type (mild, moderate or 
severe) of anaemia. However, due to the small groups of patients presenting with 
moderate or severe anaemia, we cannot draw definite conclusions on the correlation 
between severity and cause from this cohort. Moreover, it is unlikely that the severity of 
the anaemia will be of use in the determination of the underlying aetiology, since all 
causes, except unknown anaemia, were found in all three types. The severity does 
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influence a GP’s decision on the course of treatment for the patient. No patient from the 
severe cohort was found to have an unknown anaemia. GPs responded to such a low 
haemoglobin level with a swift, often immediate, referral to the hospital for an extensive 
evaluation (personal observation of author). The association between the severity of 
anaemia and GP’s behaviour could also be seen for the treatment of IDA. GPs were more 
likely to follow the current recommendations for further diagnostics and treatment in case 
the anaemia was more severe, as described in Chapter 6.    
Both renal anaemia and IDA were found more often in women, as shown in Chapter 2. For 
IDA, this could be explained by the large number of women between 50 and 54 years old, 
who may not have yet gone through menopause. The prevalence of renal anaemia 
increases with age, due to a decrease in renal function, ascribed to a reduced 
erythropoietin secretion41. It is more common in women, most likely due to the greater 
proportion of women than men in the two highest age groups 75-84 years and 85+ years 
(51.3% and 65.7% respectively). ACD, on the other hand, was more often found in men. 
This has been observed before2, though this is not a universal result42 and the exact 
significance of this finding is unclear. Whether gender will be a relevant factor in 
comprehensive anaemia diagnostics still needs to be determined. It may influence the 
actions undertaken by a GP following the initial diagnosis of anaemia and its underlying 
cause. As seen in Chapter 6, GPs are much less inclined to order an endoscopy in female 
patients with IDA, even though the current guidelines recommend this in cases where 
hypermenorrhoea has been excluded.  
 Mortality 
Anaemia was long considered to be an innocent consequence of aging and may still be 
regarded as such in daily practice. To provide a clear understanding of the aetiology of 
anaemia and the potential consequences, reliable prevalence rates of the possible causes 
and data on their influence on mortality are necessary. Both the prevalence rates and the 
association was determined in a large cohort of general practice patients newly diagnosed 
with anaemia in Chapter 2 and 3. Patients with unknown anaemia were used as reference 
group for the assessment of mortality risk.    
No ratio could be determined for haemoglobinopathy (no deaths observed during the 
follow-up period). Patients diagnosed with one of the other eight causes or with multiple 
causes did all show an increased mortality risk. These risks reached significance for the 
categories ACD, possible bone marrow disease, folic acid deficiency, renal anaemia and 
multiple causes. Associations between anaemia aetiology and mortality have been clearly 
established, but the underlying mechanisms are less clear. So far, epidemiological studies 
have been unable to establish a causal link between anaemia itself and functional decline 
in the elderly43. There is also no literature supporting a causal link between anaemia and 
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survival. It is therefore probable that the significant influence of these categories can be 
attributed to the underlying conditions. Successfully treating these conditions could 
therefore potentially reverse the increased risk, though this may be easier said than done. 
ACD and possible bone marrow disease are regularly caused by malignancies, which can 
be difficult to treat. Considering the median age of the cohort, further diagnostics or 
treatment of anaemia in general may be refused or decided against by the patient or GP, 
due to age, co-morbidities and/or overall health status.  
All-cause anaemia was also associated with an increased mortality risk when comparing 
the anaemic population with the overall Dutch population. This effect was the strongest in 
the youngest age groups. The presence of severe co-morbidities may have been a possible 
explanation for this observation. Studies in community-dwelling populations (≥ 65 years) 
found a higher prevalence of coronary heart disease, congestive heart failure, diabetes, 
malignancies, infectious disease and kidney disease in anaemic patients8,9. However, co-
morbidities were not registered in our study, so their potential presence and influence 
could not be substantiated. In the advanced age groups, it is most likely age itself that has 
a more significant influence on mortality, lessening the impact of anaemia. In the younger 
age groups, the impact of anaemia is, therefore, more pronounced.   
Chapters 5 and 6 describe the mortality risk associated with adherence and non-
adherence to the current guidelines for the treatment of ACD and IDA, respectively. The 
GPs decision on adherence was not reflected in the mortality risk for ACD patients, but for 
IDA patients a significant difference was found. Patients to whom the standard was not 
applied showed a significantly increased mortality risk compared to patients to whom the 
standard was applied. It should be noted that this survival model was not corrected for co-
morbidities. A patient’s co-morbidities and overall health status could have significantly 
influenced the GP’s decision to follow the standard and could also have influenced 
survival.  
 Further diagnostics  
Despite the widespread prevalence of anaemia there is little data available regarding how 
widely and successfully anaemia is managed by clinicians. The studies that are available, 
including cohorts of cancer patients and renal transplant recipients, indicate treatment of 
the decreased haemoglobin level itself is limited44,45. Elucidating the underlying cause of 
anaemia is essential for targeted treatment29. However, laboratory measurements do not 
always provide a clear cause, or the results recommend further invasive diagnostics. For 
example, the finding of IDA should be followed by an endoscopy unless there is a clear 
cause for the deficiency, such as hypermenorrhea or blood donation. Guidelines have 
been set up to document the recommended further diagnostics27. We evaluated the 
adherence to the national guideline for ACD and IDA, respectively (Chapters 5 and 6).  
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survival. It is therefore probable that the significant influence of these categories can be 
attributed to the underlying conditions. Successfully treating these conditions could 
therefore potentially reverse the increased risk, though this may be easier said than done. 
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treatment of anaemia in general may be refused or decided against by the patient or GP, 
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anaemia is essential for targeted treatment29. However, laboratory measurements do not 
always provide a clear cause, or the results recommend further invasive diagnostics. For 
example, the finding of IDA should be followed by an endoscopy unless there is a clear 
cause for the deficiency, such as hypermenorrhea or blood donation. Guidelines have 
been set up to document the recommended further diagnostics27. We evaluated the 
adherence to the national guideline for ACD and IDA, respectively (Chapters 5 and 6).  
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Whether any further diagnostics for ACD or IDA are actually initiated by the GP depends 
on several factors, including the patient’s age, the severity of the anaemia, any existing co-
morbidities and the patient’s wishes regarding their treatment. The IDA patients 
(described in Chapter 6) for whom the standard was not applied may have had a poorer 
health status or more co-morbidities than the IDA patients for whom the standard was 
applied. We studied a relatively elderly cohort, and the age of the patient may significantly 
influence the GP’s decision regarding which treatment strategy to follow. The GP may 
decide against further diagnostics if there are no true benefits to be gained from 
treatment due to the patients age, health status or co-morbidities. The severity of 
anaemia may also have an impact. A portion of the patients studied in Chapter 6 did not 
receive oral iron supplementation. This supplementation can give severe side effects and 
GPs may be reluctant to prescribe it if the anaemia is very mild (personal communication). 
The guideline for ACD requires further investigations to elucidate the underlying 
condition, if one is not immediately apparent, but these investigations were infrequently 
ordered. GPs may decide against further investigations if the anaemia is mild and not 
considered potentially harmful to the patient or if the patient has severe co-morbidities. 
Again, the patients age or health status may already lead to a decision against treatment, 
rendering invasive diagnostics irrelevant.  
GPs will consider both the risks and the potential benefits of any procedure when deciding 
on further evaluation of any anaemia. In patients aged 85 years or older, anaemia no 
longer significantly influences mortality (Chapter 3). Especially in this very old population, 
invasive diagnostics should be used with extreme care, since, with regards to decreasing 
mortality risks, the gain will be minimal. In all age groups and severity types of anaemia, 
the patient’s wishes will be a major factor in the GP’s decisions.  
 Treatment  
It has been suggested that the fatigue, cardiovascular complications and impaired physical 
performance often seen with anaemia are caused by the reduced oxygen-carrying capacity 
of the blood46. However, at this moment it is unclear whether reversing the anaemia itself 
(i.e. increasing the haemoglobin level) without also successfully treating the underlying 
condition can give improvements. Small trials have been conducted to analyse the effects 
of systematic erythropoietin treatment. Improvements in quality of life and a decreased 
need for blood transfusions have been reported47-49, but so have increased risk of 
thromboembolic events, increased risk of cardiovascular events, and increased mortality49-
53. Treating mild anaemia with blood transfusions is strongly discouraged43,54-56 due to 
increased mortality57,58, and is, therefore, not an option for the large majority of anaemic 
patients. Due to the central role of hepcidin in iron metabolism59, this peptide and its 
associated pathways have become the target for newly developed therapeutics for iron 
disorders. Hepcidin agonists, either mimics or stimulators of hepcidin production, may be 
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beneficial in iron overload disorders such as hemochromatosis and β-thalassemia. Patients 
with anaemia of chronic disease may benefit from hepcidin inhibitors. These may either 
inhibit hepcidin production, neutralise the peptide or interfere with the binding between 
hepcidin and the iron transporter ferroportin60-62.     
Increasing the haemoglobin level without treating the underlying aetiology could be a 
solution for patients with unexplained anaemia, since in these cases, there is no clear 
underlying condition to treat. Currently, over 25% of anaemia cases remain unexplained. 
Unknown anaemia was significantly associated with mild anaemia (Chapter 2). Yet even if 
it is mild, the association of anaemia with detrimental effects on both health and mortality 
can already be observed5,21,24,25,63-68. In addition, unknown anaemia was also associated 
with an increased mortality risk42. Treating the anaemia itself (i.e. the decreased 
haemoglobin level) without treating the underlying condition,  would also potentially help 
those patients who no longer wish for invasive diagnostics to determine any underlying 
aetiology or are unable to undergo such diagnostics due to age or severe co-morbidities. 
Improving their haemoglobin level may have positive effects on, for example, their quality 
of life. 
So far, no satisfactory results have been obtained with the currently available medications 
(e.g. erythropoietin replacement or blood transfusions) for the correction of the 
haemoglobin level alone. Therapeutics targeting hepcidin seem promising but need to 
achieve a very solid safety profile to justify their use in daily practice.   
 Limitations of population database 
All studies described in part I of this thesis use a large, population-based database of 
general practice patients with newly diagnosed anaemia. Unfortunately, this database 
does have several limitations. The study has an epidemiological setting and the criteria 
used to define the different causes of anaemia cannot strictly be regarded as diagnostic, 
even though the definitions were based on the GP standard in use during the study period 
and on the knowledge of experienced haematologists, internists and clinical chemists. The 
observation of a normalised haemoglobin level after treatment of the underlying aetiology 
is the most reliable way of determining whether or not the initial diagnosis was correct. 
Since we did not perform a follow-up on the included patients, this confirmation was not 
available to us. For example, the presence of ACD, IDA and renal anaemia in the 
macrocytic cohort; a normalisation of both haemoglobin and MCV after treating these 
conditions would have provided firmer evidence that the laboratory results connected to 
ACD, IDA and renal anaemia were associated with the observed decrease in haemoglobin 
and increased MCV. 
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The diagnosis of anaemia was based on a single haemoglobin measurement. The study 
protocol did not include a repeat of this measurement. During the follow-up period, a 
change in the haemoglobin level of a patient may occur. A longer follow-up results in a 
higher probability of such a change occurring24. This highlights one possible drawback for 
using this database to assess mortality, since anaemia and its underlying cause or causes 
may have been resolved at the time of death. Therefore, an association between anaemia 
and mortality can be established, but not a causal link. Nonetheless, the described 
database is one of the largest-population based databases with anaemic general practice 
patients and provides a solid basis for further research into anaemia in this population.  
Digital microscopy 
Laboratory techniques play a vital role in the evaluation of anaemia. One of the key 
components of such an evaluation is the peripheral blood smear (PBS). Cell counters give 
an alert when the laboratory measurements are suspect for a bone marrow disease, which 
is not uncommon in anaemic patients. A PBS is then generated for further evaluation. For 
decades, morphological assessment of the PBS has been done manually, using a light 
microscope. This method is prone to inter-observer variability, requires highly and 
continuously trained personnel and is time-consuming69-71. Digital microscope (DM) 
systems have been developed for the automation and standardisation of morphological 
assessment. To allow DM systems to become fully accepted as the replacement of manual 
assessment, the current gold standard, these systems need to be extensively validated. 
Two steps of the validation process are described in this thesis.  
 Validation DM systems 
Chapter 7 describes the determination of the inter-laboratory reproducibility. Four 
independent DM systems of the same brand and product type, operated at different 
locations and by local operators, can achieve comparable results for the main blood cell 
classes (neutrophils, lymphocytes, monocytes, eosinophils) and blast cells. The variability 
was high for basophils, an observation also made when comparing manual counts of this 
cell class71,72. This is most likely due to the low prevalence of these cells in the studied 
samples. The problem is solved by including more samples, which increases the number of 
counted basophils. Chapter 8 describes a large database of 1.4 million leukocytes used to 
compare the DM to the gold standard. The size of the database and the mix of normal and 
abnormal blood smears allows for the definite confirmation that the DM systems are 
capable of achieving excellent accuracy for the five main blood cell classes and can attain a 
sensitivity of 100% for the detection of blast cells. The system is less capable of properly 
classifying the less common cell classes and will generally classify these into one of the five 
main classes. Since these less common classes can be clinically significant, the DM still 
needs to be supported by a manual expert at this point in time.  
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 Future abilities leukocyte morphology 
Currently, the DM is used to pre-classify the PBS, after which the manual expert assesses 
the slide using the overview option of the software and re-classifies the analysed cells 
where necessary. This workflow saves time and allows for the digital storage of the slide. 
The future goal is to fully automate the processing of a PBS, including the analysis, without 
any manual intervention. Currently this is feasible for the five main blood cell classes, but 
the performance of the DM for the less common classes is lacking. The algorithms used by 
the DM to recognise the less common cell classes need to be improved, before this 
completely automated processing can be put into practice. In addition, the DM will have 
to be tested again with a large database containing normal and abnormal blood smears to 
confirm, that the less common cell classes are properly recognised and classified. The 
inter-laboratory variation for these improved systems will need to be determined for all 
the cell classes, instead of just the five main classes and blast cells. Any future analysis will 
require larger sample numbers than those included in the study described in Chapter 7.  
 Future perspectives: erythrocyte and bone marrow morphology 
A recent development in DM systems is the automated recognition and classification of 
red blood cell morphology. DM systems can recognise classes such as target cells, 
teardrop cells, and sickle cells, and abnormalities such as microcytosis73,74, which allows 
the DM to aid in the quick recognition of severe conditions. An example is the diagnosis of 
thrombotic thrombocytopenic purpura (TTP) and haemolytic-uremic syndrome (HUS), 
which are both characterised by an increase in schistocytes. The cell class is accurately 
detected by the DM, allowing for the proper recognition of both TTP and HUS74. The 
current software is also capable of recognising inclusions within erythrocytes such as 
malaria parasites. The red blood cell module on the DM is currently undergoing validation 
for use in daily practice as a support for morphology experts. The first results are 
promising, but are indicating that the software requires further development, for example 
to improve the differentiation between observed inclusions.  
Another aspect of morphology assessment is the analysis of a bone marrow sample 
through the light microscope. The DM module that should allow for the automated 
analysis of these samples is currently in development. The main issue appears to be 
‘teaching’ the system where to look in the smear produced from the bone marrow 
sample. Scanning the slide requires a lot of computational power and takes a lot of time. 
These problems will have to be solved before the bone marrow module can become a 
valuable addition to the diagnostic workflow.   
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Conclusions 
We analysed a large cohort of general practice patients (≥ 50 years) with newly diagnosed 
anaemia. Our results show MCV is an unreliable parameter when excluding causes of 
anaemia or deciding on further diagnostics for the evaluation of anaemia. MCV should, 
therefore, lose its central role in anaemia evaluation. In case the GP suspects the presence 
of anaemia, a standardised protocol should be ordered instead of allowing MCV to be 
leading in any diagnostic decisions. The association between anaemia and mortality was 
again confirmed. For the first time the impact of less prevalent causes was established. 
Whether this association is seen because anaemia is a marker of underlying disease or 
because there exists a more causal connection between anaemia and mortality, remains 
to be determined.  
Digital microscopy has proven itself to be a reliable tool for the analysis of the peripheral 
blood smear. Considering the continuing development of these systems and the advancing 
digitalisation of the laboratory workplace, digital microscopy will become a viable 
alternative for manual assessment and, in time, replace the human component.  
The association of anaemia with detrimental effects on health and mortality has been 
extensively documented. It is now time to study possible treatment options and to 
determine whether actively treating anaemia itself is a viable option for improving 
patients’ prospects. A thorough evaluation of anaemia will remain necessary, as quickly 
determining the underlying aetiology gives access to rapid and proper treatment. Future 
options for this evaluation include developing a digitalised algorithm and the further 
automation and standardisation of the morphological analysis of leukocytes, erythrocytes 
and thrombocytes. These options and increased awareness of the detrimental effects of 
anaemia will hopefully ensure that anaemia will no longer be considered an innocent 
bystander, but will receive the full attention it requires.   
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Conclusions 
We analysed a large cohort of general practice patients (≥ 50 years) with newly diagnosed 
anaemia. Our results show MCV is an unreliable parameter when excluding causes of 
anaemia or deciding on further diagnostics for the evaluation of anaemia. MCV should, 
therefore, lose its central role in anaemia evaluation. In case the GP suspects the presence 
of anaemia, a standardised protocol should be ordered instead of allowing MCV to be 
leading in any diagnostic decisions. The association between anaemia and mortality was 
again confirmed. For the first time the impact of less prevalent causes was established. 
Whether this association is seen because anaemia is a marker of underlying disease or 
because there exists a more causal connection between anaemia and mortality, remains 
to be determined.  
Digital microscopy has proven itself to be a reliable tool for the analysis of the peripheral 
blood smear. Considering the continuing development of these systems and the advancing 
digitalisation of the laboratory workplace, digital microscopy will become a viable 
alternative for manual assessment and, in time, replace the human component.  
The association of anaemia with detrimental effects on health and mortality has been 
extensively documented. It is now time to study possible treatment options and to 
determine whether actively treating anaemia itself is a viable option for improving 
patients’ prospects. A thorough evaluation of anaemia will remain necessary, as quickly 
determining the underlying aetiology gives access to rapid and proper treatment. Future 
options for this evaluation include developing a digitalised algorithm and the further 
automation and standardisation of the morphological analysis of leukocytes, erythrocytes 
and thrombocytes. These options and increased awareness of the detrimental effects of 
anaemia will hopefully ensure that anaemia will no longer be considered an innocent 
bystander, but will receive the full attention it requires.   
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Anaemia is a leading health problem worldwide with a high burden in the most vulnerable 
populations: children below five years of age and people aged 85 years and above 1,2. It is 
generally defined by a decreased haemoglobin level and was long considered an innocent 
consequence of aging in the elderly population. However, data on the association of 
anaemia with detrimental effects on health aspects, quality of life and survival have been 
steadily accumulating over the past decade. Currently, there are only a few options for the 
treatment of the decreased haemoglobin level itself. To alleviate the anaemia, targeted 
treatment of the underlying aetiology is necessary. Reliable prevalence rates for the 
different causes of anaemia and decisive diagnostic guidelines are important aids for the 
physician with the diagnosis and treatment of anaemia and its aetiology. 
In Part I of this thesis we described the extensive analysis of a large cohort of general 
practice patients newly diagnosed with anaemia. Chapter 2 provides reliable prevalence 
rates for nine different causes and for unknown or unexplained anaemia. The distribution 
of these ten categories of aetiology over the different types of anaemia (mild, moderate 
or severe, based on haemoglobin), age groups (50-64, 65-74, 75-84 and 85+ years), 
genders, and classes of anaemia (microcytic, normocytic or macrocytic, based on mean 
corpuscular volume (MCV)) was evaluated. The most striking results included the high 
prevalence of iron deficiency in patients with a severe anaemia and the statistically 
significant increase in the prevalence of renal anaemia with every age group. Current 
algorithms for the evaluation of anaemia follow a classification based on MCV but the 
validity of this classification has been challenged. The data in Chapter 2 confirmed that, in 
general practice, the predictive value of MCV is not strong enough to justify excluding 
causes based solely on this parameter. Therefore, existing MCV-based algorithms for the 
evaluation of anaemia should be reconsidered.  
The impact of the aetiology on the mortality risk of anaemic general practice patients was 
analysed in Chapter 3. All causes except haemoglobinopathy (no recorded deaths) were 
associated with an increased mortality risk. This increase reached statistical significance 
for the categories anaemia of chronic disease (ACD), possible bone marrow disease, folic 
acid deficiency, renal anaemia and multiple causes and is most likely due to underlying 
conditions associated with these causes, such as malignancies. The standardised mortality 
ratios (SMR) were calculated per five-year age group and gender by comparing the 
mortality risks of the complete anaemic cohort (all-cause anaemia) and the general Dutch 
population. Especially in the younger age groups, anaemia was associated with a severe 
impact on mortality risk in both men and women. From age 85 years and older, anaemia 
was no longer associated with an increased risk. In this population, invasive diagnostics to 
determine the underlying cause of anaemia should be used with great restraint. The risks 
may outweigh the benefits and it is unclear if any improvement in overall survival can be 
achieved.  
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The macrocytic cohort of the population database was analysed separately and described 
in Chapter 4. ACD, iron deficiency anaemia (IDA) and renal anaemia were frequently found 
in this cohort, though these causes are not traditionally described as macrocytic. This 
finding further supports the results found in Chapter 2, concerning the weak predictive 
value of MCV in general practice. The influence of six different categories of causes on the 
mortality risk of this cohort was assessed. Univariate analyses showed the lowest 5-year 
survival rate in patients with renal anaemia, followed by nutrient deficiency (iron, vitamin 
B12 and folic acid), ACD, multiple causes, and other causes (haemolysis, documented 
alcohol abuse, possible bone marrow disease, and other). Patients with unknown anaemia 
had the highest 5-year survival rate. Multivariate analysis was also performed but no 
significant results were found.   
There is little information on the treatment strategies for anaemia applied in daily 
practice3,4. Aetiologies such as ACD and IDA require further diagnostics since the possible 
underlying conditions for these categories are diverse and extensive. The adherence of 
general practitioners in the Netherlands to the national guidelines for ACD and IDA was 
analysed in Chapters 5 and 6. As seen in Chapter 5, the guideline was applied in the 
majority of ACD cases, but oral iron supplementation, which is discouraged, was still 
prescribed in a substantial number of patients. While underlying conditions could not 
always be established, even after further diagnostics, a survival analysis showed no 
difference between the survival of patients with or without an established underlying 
condition.  As described in Chapter 6, adherence to the guidelines for IDA was seen in a 
minority of patients. An increased mortality risk was found for patients in whom the 
guideline was not applied. General practitioners may have decided against following the 
guideline, which includes a potential risky endoscopy, based on factors such as age, co-
morbidities, health status and the patient’s wishes. Apart from age, these factors were not 
recorded, and could not be included in our statistical survival model.   
The morphological assessment of the peripheral blood smear remains an important part 
of laboratory diagnostics. For decades this assessment has been done manually using a 
light microscope. During the last decade, digital microscopy (DM) systems have developed 
into reliable diagnostic tools. DM systems allow for an automated and standardised 
morphological assessment but do need to be extensively validated before they can be 
accepted as the standard diagnostic tool in blood morphology.  
Two steps in the validation process of DM systems are described in Chapters 7 and 8. In 
Chapter 7 the inter-laboratory variation was determined. Independently operated DM 
systems yield reproducible pre-classification results when classifying neutrophils, 
lymphocytes, monocytes, and eosinophils. Blast cells were also detected correctly and 
with only minor variation between the systems. The pre-classification performance for 
basophils showed considerable inter-laboratory variation, which was most likely due to 
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the low incidence of these cells in the used samples. We described the analysis of a large 
database consisting of 1.4 million leukocytes in Chapter 8. Using this database, we 
determined the accuracy of the DM system for the classification of a wide range of 
leukocyte classes. The DM system showed an excellent accuracy for the five main cell 
classes: neutrophils, lymphocytes, monocytes, eosinophils, and basophils. Blast cells were 
detected with 100% sensitivity. The detection of the less common cell classes 
(promyelocytes, myelocytes, metamyelocytes, and plasma cells) was less accurate. The 
rare cell classes (promonocytes, prolymphocytes, hairy cells, and cleaved cells) cannot yet 
be detected by the DM system. Therefore, manual intervention remains necessary at this 
point in time to ‘help’ the system with the less common and rare classes as well as the 
occasional outlier. The current pre-classification performance of DM systems is a 
significant step towards the acceptance of these systems as the standard diagnostic tool 
for morphological assessment.  
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 Anemie is een van de meest voorkomende gezondheidsproblemen in de wereld met een 
hoge prevalentie in de meest kwetsbare populaties, namelijk kinderen jonger dan vijf jaar 
en mensen van 85 jaar en ouder1,2. Het wordt gekarakteriseerd door een verlaagde 
concentratie hemoglobine. In de oudere populatie werd anemie lang gezien als een 
onschuldige consequentie van het ouder worden, maar de bewijzen voor de associatie 
tussen anemie en schadelijke effecten op gezondheid, kwaliteit van leven en mortaliteit 
stapelen zich op. Op dit moment zijn er beperkte opties voor het behandelen van de 
verlaagde concentratie hemoglobine zelf. Om anemie te verhelpen is een gerichte 
behandeling van de onderliggende etiologie noodzakelijk. Betrouwbare prevalentie cijfers 
voor de verschillende oorzaken en betrouwbare richtlijnen zijn belangrijke hulpmiddelen 
voor de arts bij de diagnose en behandeling van anemie en de onderliggende oorzaken. 
Deel I van dit proefschrift beschrijft de uitgebreide analyse van een groot cohort van 
huisartspatiënten met een nieuw gediagnosticeerde anemie. Hoofdstuk 2 geeft 
betrouwbare prevalentie cijfers voor negen verschillende oorzaken en voor onbekende 
anemie. De verdeling van deze tien etiologie categorieën over de verschillende typen 
anemie (mild, matig en ernstig, gebaseerd op de hemoglobine concentratie), 
leeftijdsgroepen, (50-64, 65-74, 75-84 en 85+ jaar), geslacht en klassen van anemie 
(microcytair, normocytair en macrocytair, gebaseerd op het mean corpuscular volume 
(MCV)) werd geanalyseerd. Twee van de meest opvallende resultaten waren de hoge 
prevalentie van ijzergebreksanemie in patiënten met een ernstige anemie en de 
significante verhoging van de prevalentie van renale anemie bij elke leeftijdsgroep. De 
huidige algoritmes voor de evaluatie van anemie volgen een classificatie gebaseerd op 
MCV maar de validiteit van deze classificatie wordt tegenwoordig in twijfel getrokken. De 
resultaten in Hoofdstuk 2 bevestigen dat de voorspellende waarde van MCV in de 
huisartsenpraktijk niet sterk genoeg is om oorzaken uit te sluiten op enkel deze 
parameter. Daarom moeten de bestaande, op MCV gebaseerde algoritmes voor de 
evaluatie van anemie herzien worden.  
De invloed van de etiologie op het mortaliteitsrisico van anemische huisartspatiënten 
wordt geanalyseerd in Hoofdstuk 3. Alle oorzaken, behalve hemoglobinopathie (geen 
geregistreerde sterfgevallen), werden geassocieerd met een verhoogd mortaliteitsrisico. 
Deze verhoging was significant voor de oorzaken anemie der chronische ziekten (ACD), 
mogelijke beenmergziekte, foliumzuur deficiëntie, renale anemie en de categorie 
meerdere oorzaken. Dit is hoogstwaarschijnlijk het gevolg van onderliggende condities die 
met deze oorzaken geassocieerd zijn, zoals maligniteiten. De standardised mortality ratio’s 
(SMR) werden berekend per leeftijdsgroep van vijf jaar en geslacht door het 
mortaliteitsrisico van het complete anemische cohort (alle oorzaken) te vergelijken met 
het risico van de algemene Nederlandse populatie. Vooral in de jongere leeftijdsgroepen 
werd anemie geassocieerd met een ernstige impact op het mortaliteitsrisico van zowel 
mannen en vrouwen. Bij patiënten van 85 jaar en ouder werd dit verhoogde risico niet 
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langer gezien. In deze populatie moet invasieve diagnostiek ten einde het vaststellen van 
de onderliggende oorzaak, dan ook met grote terughoudendheid toegepast worden.  
In Hoofdstuk 4 wordt het macrocytaire cohort van de populatie database apart 
geanalyseerd. Anemie der chronische ziekte, ijzerdeficiëntie anemie en renale anemie 
werden frequent gevonden in dit cohort, terwijl deze oorzaken traditioneel niet als 
macrocytair worden beschouwd. Deze resultaten ondersteunen de bevindingen in 
Hoofdstuk 2, aangaande de zwakke voorspellende waarde van MCV in de 
huisartsenpraktijk. De invloed van zes verschillende categorieën op het mortaliteitsrisico 
werd onderzocht in dit cohort. Univariaat analyses lieten de laagste 5-jaars overleving zien 
bij patiënten met renale anemie, gevolgd door nutriënt deficiëntie (ijzer, vitamine B12 en 
foliumzuur), anemie der chronische ziekten, meerdere oorzaken, en overige oorzaken 
(hemolyse, gedocumenteerd alcoholmisbruik, mogelijke beenmergziekte en overig). 
Patiënten met onbekende anemie hadden de hoogste 5-jaars overleving. Multivariaat 
analyse werd ook uitgevoerd maar gaf geen significante resultaten. 
Er is weinig informatie beschikbaar over de behandeling van anemie in de dagelijkse 
praktijk3,4. Oorzaken zoals ACD en ijzerdeficiëntie anemie (IDA) vereisen verdere 
diagnostiek aangezien de mogelijke onderliggende etiologie voor deze categorieën erg 
divers is. In Hoofdstuk 5 en 6 wordt geanalyseerd hoe goed huisartsen de nationale 
richtlijnen aangaande deze twee oorzaken volgen. Zoals te lezen in Hoofdstuk 5 werd de 
richtlijn in de meerderheid van ACD patiënten toegepast, al werd er, tegen de richtlijn in, 
nog steeds ijzersuppletie voorgeschreven bij een aanzienlijk deel van de patiënten. Een 
onderliggende oorzaak werd niet altijd gevonden, ondanks verdere diagnostiek. Een 
overlevingsmodel liet geen verschil zien tussen de overleving van patiënten met en zonder 
een vastgestelde onderliggende oorzaak. In Hoofdstuk 6 wordt beschreven dat de 
richtlijnen voor de behandeling van IDA in een minderheid van patiënten toegepast werd. 
Een verhoogd mortaliteitsrisico werd gevonden voor de patiënten bij wie de richtlijn niet 
gevolgd werd. Huisartsen kunnen ervoor gekozen hebben de richtlijn, inclusief een 
mogelijk risicovolle endoscopie, niet te volgen vanwege factoren zoals leeftijd, co-
morbiditeit, gezondheid en wensen van de patiënt. Op leeftijd na, konden deze factoren 
niet meegenomen worden in ons overlevingsmodel. 
De morfologische beoordeling van een perifere bloeduitstrijk blijft een belangrijk 
onderdeel van laboratorium diagnostiek. Decennialang werd deze beoordeling manueel 
uitgevoerd met behulp van de lichtmicroscoop. Tijdens het laatste decennium zijn digitale 
microscopie (DM) systemen ontwikkeld tot betrouwbare diagnostische hulpmiddelen. DM 
systemen zorgen voor een geautomatiseerde en gestandaardiseerde morfologische 
beoordeling maar moeten een uitgebreide validatie ondergaan voordat ze geaccepteerd 
kunnen worden als de standaard diagnostiek op dit gebied.  
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Twee stappen van dit validatie proces worden beschreven in Hoofdstuk 7 en 8. In 
Hoofdstuk 7 is de inter-laboratorium variabiliteit vastgesteld. DM systemen gaven 
onafhankelijk van elkaar reproduceerbare pre-classificatie resultaten bij de classificatie 
van neutrofielen, lymfocyten, monocyten, en eosinofielen. Blast cellen worden ook 
correct gedetecteerd en met een minimale variatie. De pre-classificatie van basofielen liet 
wel een flinke inter-laboratorium variatie zien. Dit was hoogstwaarschijnlijk het gevolg van 
de lage incidentie van deze cel klasse in de gebruikte monsters. In Hoofdstuk 8 beschrijven 
we de analyse van een grote database met 1.4 miljoen leukocyten. Met behulp van deze 
database werd de nauwkeurigheid van een DM systeem bepaald voor een heel scala aan 
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